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Despite effective antiretroviral therapy (ART), HIV-1 persists in all infected individuals as proviral 
DNA integrated within long-lived resting memory CD4+ T cells. The population of infected CD4+ T cells 
carrying replication-competent proviruses is the major barrier to HIV-1 cure. Several lines of evidence have 
demonstrated that cellular proliferation of infected cells contributes to HIV-1 persistence. This proliferative 
process is complicated by the fact that most infected cells carry defective proviruses and cells harboring 
replication-competent HIV die quickly upon viral reactivation. To elucidate mechanisms that drive 
proliferation of HIV-1-infected CD4+ T cells, we followed proliferation of cells carrying replication-competent 
HIV-1 induced by antigen stimulation or cytokine treatment and demonstrated that latently infected cells 
carrying replication-competent HIV can proliferate in response to both stimuli. To study the dynamics of cells 
carrying replication-competent HIV-1, we sampled infectious virus from p24+ wells of the quantitative viral 
outgrowth assay at multiple time points spanning 2-3 years. Sequencing of replication-competent HIV-1 at 
multiple time points revealed that expanded cellular clones containing replication-competent HIV-1 is 
common. While some clones persist for 2-3 years, other clones wax and wane overtime. A similar pattern is 
observed with virus clones in the residual viremia. This observation with residual viremia supports our 
hypothesis that viruses in plasma are produced by activation of latently infected cells carrying replication-
competent HIV-1 rather than ongoing cycles of virus replication. In addition, this supports our hypothesis 
that antigens drive proliferation of cells carrying replication-competent HIV-1 and activate some of the cells, 
leading to virus production. The observed patterns with proviruses in the latent reservoir and viruses in the 
residual viremia do not support a continuous proliferative process related to HIV-1 integration into cancer-
associated genes.  
These studies are also being extended to cells carrying defective proviruses. A previous study has 
demonstrated that defective HIV-1 proviruses can be transcribed, translated or even recognized by HIV-1 
specific CD8+ T cells. We hypothesized that defective proviruses may have a proliferative advantage that 
allows the cells carrying defective proviruses to proliferate more than cells carrying intact proviruses. Given 
that intact proviruses only account for 2% of total proviruses in patients on long-term suppressive ART, 
infected cells carrying defective proviruses greatly outnumber the cells harboring intact proviruses in vivo. 
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We hypothesized that in vitro, cells carrying defective proviruses would proliferate upon T cell activation 
while cells harboring intact proviruses capable of viral gene expression, would die upon T cell activation due 
to viral cytopathic effects. Therefore, cells carrying either defective proviruses and or intact proviruses would 
show different proliferation dynamics upon TCR activation in vitro. To determine whether cells infected with 
intact or defective proviruses would proliferate to the same extent, we subjected single HIV-1  infected cells 
to 4 rounds of anti-CD3/CD28 stimulation in a microculture system and used a novel  droplet digital PCR 
assay (intact proviral DNA assay; IPDA) to  quantitate the number of intact and defective proviral DNA 
sequences in infected cells. We demonstratethat cells carrying defective proviruses were capable of 
enormous expansion with in vitro anti-CD3/CD28 stimulation, while cells harboring intact proviruses were 
rarely detected and showed little proliferative potential. Integration site analysis of clones expanded in vitro 
demonstrated that HIV-1 provirus integration into cancer-associated gene is not required for proliferation of 
HIV-1-infected cells. Additionally, we sequenced the cell clones that proliferated the most in vitro and found 
that proviruses in these clones were highly defective. These microculture experiments revealed a profound 
proliferation defect for cells carrying intact proviruses upon anti-CD3/CD28 stimulation.  
To explore whether cells carrying intact and defective proviruses show similar dynamics in vivo, we 
examined longitudinal samples collected 2-8 years apart using the IPDA. We found that the half-life of 
infected was ~44 months, consistent with a previous measurements of the latent reservoir as measured with 
a quantitative viral outgrowth assay (QVOA), while cells carrying defective proviruses showed greater 
variability among patients. Collectively, my thesis has measured the dynamics of CD4+ T cells carrying 
different types of proviruses and has provided insight into mechanisms that may contribute to proliferation 
of HIV-infected cells in vivo.  
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Despite prevention efforts, there are approximately 36.7 million people living with human 
immunodeficiency virus type 1 (HIV-1) infection worldwide. To date, only one person has been cured of an 
established HIV-1 infection.  This has suggested that cure of HIV infection is possible. I will describe this case 
and other near cure cases and discuss why the latent reservoir in resting, memory CD4+ T cells is the major 
barrier to curing HIV-1 infection. I will also review HIV-1 latent reservoir dynamics as measured by current 
assays and present a novel assay that allows quantification of infected cells carrying different types of HIV-1 
proviruses.  
HIV-1 is a lentivirus that mainly replicates in activated CD4+ T lymphocytes and kills them quickly, 
usually within a day.  In untreated infected individuals, infected CD4+ cells gradually decline over the course 
of several years. AIDS (acquired Immunodeficiency syndrome) is defined when the CD4+ T cells reach a 
threshold of 200 cells/ul in the blood and the infected individual is susceptible to opportunistic infections. 
AIDS is a condition in humans in which progressive destruction of CD4+ T cells allows life-threatening 
infections and cancers to thrive. Without lifelong antiretroviral therapy, most infected individuals will die 
from AIDs. The disease that we now call AIDS was first described in previously healthy homosexual men (1).  
Four patients had no preexisting immunodeficiency, but were anergic and lymphopenic, showing no 
lymphocyte proliferative responses to antigens. These patients contracted multiple viral infections and had 
prolonged fevers of unknown origin (1).  Cytomegalovirus (CMV) was recovered from all four patients 
studied, but the persistence of fever and the occurrence of leukopenia, lymphopenia and opportunitstic 
infection are not features of CMV infection in normal hosts. Therefore doctors concluded that the CMV and 
opportunistic infections might be a result of immunodeficiency observed in these patients (1).   
To date, only a single person, the “Berlin patient”, Timothy Brown, has been cured of an established 
HIV-1 infection.  Mr. Brown was HIV-1 infected and doing well on antiretroviral therapy when he developed 
acute myeloid leukemia. To treat his leukemia, he received a bone marrow transplant from a carefully 
selected donor who was homozygous for a 32 base pair deletion in CCR5, a receptor that is critical for HIV-1 
entry into CD4+ T cells. The Berlin patient has remained off antiretroviral therapy since the time of his initial 
transplant, now going on 10 years, and shows no sign of HIV-1 infection after the transplant (2). The Berlin 
patient is an important proof-of-principle case. Mr. Brown’s immune system, including latently infected 
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resting CD4+ T cells were largely eliminated by the conditioning regimen that he received prior to his 
transplant and by graft vs. host disease after the transplant. Even if small numbers of infected cells remained 
and they produced virus, that virus could not reignite infection because Mr. Brown’s new immune system was 
resistant to HIV-1 infection. However, this approach is not feasible for the 35 million infected individuals 
throughout the world since bone marrow transplant is a risky and expensive procedure and would most 
likely only be done on patients with certain malignancies. Efforts to reproduce this sterilizing cure in other 
patients have not resulted in additional cure. Two other patients, referred to as the “Boston patients”, 
received transplants from donors with the wild-type CCR5 for malignancies to recapitulate the Berlin patient 
case. The Boston patients were different from the Berlin patient since their donor cells were fully susceptible 
to HIV-1 infection. These two patients remained on cART during the transplant period and for several years 
thereafter.  When a variety of different assays to detect HIV-1 were negative, antiretroviral therapy was 
stopped because it was thought that these 2 patients were cured. Neither patient had detectable HIV-1 DNA in 
peripheral blood mononuclear cells (PBMCs) nor was infectious virus was recovered from co-cultures, which 
suggested elimination of infected cells in these patients. However, viral rebound was observed in the Boston 
patients 3 and 8 months after discontinuing cART. These cases demonstrate the presence of a stable latent 
reservoir in infected individuals and this latent reservoir persists for years with cART. It is essential to 
eliminate the latent reservoir to achieve a sterilizing cure.  
Another case that provides insight into cure strategy is the “Mississippi Baby” (3). The child was born 
prematurely in a Mississippi clinic in 2010 to an HIV-1-infected mother who did not receive antiretroviral 
medication during pregnancy and was not diagnosed with HIV infection until the time of delivery. Because of 
the high risk of HIV-1 exposure, the infant was put on cART at 30 hours of age. Within several days of birth, 
the infant was diagnosed of HIV-1 infection. The baby was kept on cART until 18 months of age but was no 
longer receiving treatment afterwards. When medical staff saw the child again 5 months later, the child had 
undetectable HIV-1 level and showed no HIV-1 specific antibodies. The child continued to do well in the 
absence of cART and showed no sign of HIV-1 infection until recently. The child, now almost 4 years of age, 
was found to have detectable HIV-1 levels in the blood and decreased levels of CD4+ T cells. The case of the 
Mississippi baby child indicated that early antiretroviral treatment did not completely eliminate the latent 
reservoir, but it may alter the establishment and long-term persistence of HIV-1 infection.  
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Although combination antiretroviral therapy (cART) reduces viremia to undetectable levels, cART is 
not curative, and infected individuals must remain on therapy for life. Here I will review the barrier to 
achieving a cure by first discussing viral dynamics in infected individuals.  I will then discuss potential cure 
strategies some of which are currently in various clinical trials. The main target of HIV-1 is activated CD4 T 
lymphocytes (4). The HIV-1 replication cycle starts with virus binding to cell surface receptor CD4 and 
chemokine co-receptors CXCR4 or CCR5; cell entry, reverse transcription of the viral RNA to double stranded 
cDNA; uncoating of the viral capsid, nuclear import of viral cDNA within the pre-integration complex; and 
DNA integration (4). Entry of virus requires interaction with CD4 and the chemokine coreceptors, CCR5 or 
CXCR4 (5, 6). However, viral entry into target cells does not guarantee viral replication due to the existence of 
host restriction factors that can target HIV-1. These host restriction factors include Apolipoprotein B mRNA-
editing enzyme 3G (APOBEC3G) and SAMHD1 (7). Following transmission, there is rapid virus replication in 
activated CD4+ T cells and a rapid increase in the level of plasma virus (4). This increase is exponential. This 
exponential virus replication generates immune responses that reduce viremia to a quasi-stable set point in 
about one month.  This exponential virus replication drives CD4+ T cell depletion, leading eventually to fatal 
immunodeficiency in an untreated patient. However, combination antiretroviral therapy causes rapid, 
exponential biphasic decay in plasma virus (viremia) to below the limit of clinical detection, 50 copies of viral 
RNA/ ml plasma. Although ART cannot target the latent reservoir, clinical studies have demonstrated that an 
optimal ART regimen can inhibit ongoing cycles of HIV-1 replication. The first antiretroviral drug approved 
by FDA is zidovudine (3’- azido-3’-deoxythymidine (AZT)), a thymidine analogue that inhibits reverse 
transcription of HIV-1 (8-10). However, AZT monotherapy selects for drug resistance, which in turn spurred 
the development of other classes of drugs, including: other nucleoside analogue reverse transcriptase 
inhibitors (NRTIs), protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), 
fusion inhibitors, entry inhibitors and integrase inhibitors. Combination antiretroviral therapy (cART) 
became a standard treatment regimen that reduced HIV-1 infection to a manageable, chronic disease (11, 12). 
The antiretroviral drugs block new cells from becoming infected but do not prevent virus release from 
infected cells that already have an integrated provirus. Therefore, the biphasic exponential decay in viremia 
after initiation of cART reflects the rapid turnover of two infected cell populations that have very short half-
lives and produce most of the plasma virus. Unfortunately, this decay does not continue but rather plateaus at 
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a new steady state of ~ 1 copy virus /ml plasma (13).  This small amount of residual viremia is not due to 
continuous, ongoing cycles of virus replication because if you intensify a 3-drug antiretroviral regimen by 
adding a fourth, new drug, residual viremia does not go down (14-19). Rather, residual viremia reflects 
viruses that are being released by a third population of infected cells that were infected prior to the start of 
antiretroviral therapy and have an extremely long half-life.  This population of infected cells are latently 
infected, resting memory CD4+ T cells and they arise as a consequence of the normal biology of CD4+ T cells. 
Upon encountering their specific cognate antigen, resting CD4+ T cells become activated and proliferate, 
generating many activated effector cells with the same antigen specificity. At the conclusion of the immune 
response, most of these activated, effector cells die, but some survive and return back to a resting memory 
state as long-lived memory CD4+ T cells. Memory cells allow for future responses to the same antigen.  HIV-1 
replicates mainly in activated CD4+ T cells, and these productively infected cells die quickly, usually within 
one day. However, if activated cells are infected with HIV-1 during the transition back to a resting memory 
state, then this results in a stably integrated but transcriptionally silent form of the viral genome in a long-
lived memory CD4+ T cell, allowing viral persistence through mechanisms that maintain lifelong immunologic 
memory. In resting memory CD4+ T cells, HIV-1 gene expression is turned off as host transcription factors 
necessary for viral transcription are sequestered in the cytosol under resting conditions (20). Our lab many 
years ago developed assays to detect the presence and persistence of latently infected cells in patients virally 
suppressed on cART (21-26). Latently infected resting CD4+ T cells are present in all individuals infected with 
HIV-1. The presence of this population of latently infected cells was demonstrated by a quantitative viral 
outgrowth assay (QVOA). This population of infected cells is present at a very low frequency in patients; ~ 
1/106 resting CD4+ T cells are latently infected with replication competent virus.  However, longitudinal 
analysis in virally suppressed patients demonstrated that this infected cell population has an extremely long 
half-life of 44 months (27). Our analysis further showed that it would take ~ 70 years for a population of one 
million of these infected cells to turn over thereby guaranteeing that patients need to be on antiretroviral 
therapy for life. Therefore, HIV-1 infection is not curable due to the persistence of a small number of latently 
infected memory CD4+ T cells harboring replication-competent proviruses (23-25).  
Different curative strategies targeting the latent reservoir have been proposed. The “sterilizing cure” 
approach involves purging the body of all latent proviruses so no virus would restart the infection if cART 
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were stopped. The “functional cure” approach would instead equip the immune system with the ability to 
control the virus without antiretroviral therapy (28, 29). The Berlin patient is a proof of principle case for the 
“sterilizing cure” approach but this approach could not be applied to most infected individuals.  One potential 
approach to reduce the latent reservoir is known as “shock and kill” (30, 31). This strategy aims at inducing 
proviral expression to enable clearance of virally infected cells (32). In order to induce viral expression, T cell 
activation may be necessary. Early attempts to reactivate virus production via global T cell activation led to 
unexpected high levels of immune activation and were toxic to patients (33). Therefore, newer approaches 
have involved reversing latency without inducing T cell activation (33). The “shock-and-kill” strategy for HIV 
eradication envisions reversing latency by inducing viral gene expression so that infected cells die from viral 
cytopathic effects or immune clearance. A number of mechanistically distinct latency-reversing agents (LRAs) 
have been identified using in vitro models of latency. These include histone deacetylase (HDAC) inhibitors, 
thought to function by modifying the epigenetic environment around the site of provirus integration (34, 35); 
disulfiram, which involves nuclear factor kappa-light-chain-enhancer of activated B cells (NF- κB) (32, 36, 
37); the bromodomain-containing protein 4 (BRD4) inhibitor JQ1, which elicits transcription through positive 
transcription elongation factor (P-TEFb) (38-41); and protein kinase C (PKC) agonists such as bryostatin-1 
and prostrain, which have a major role in signaling pathway downstream of T cell receptor engagement (42-
45). Studies have shown that LRAs do not significantly cause proviral expression in patient cells (46). Clinical 
trials in patients on ART with disulfiram and HDAC inhibitors such as vorinostat, romidepsin and 
panobinostat showed inconsistent results (35, 36, 47-49). Most importantly, no LRA has been demonstrated 
to reduce the size of the latent reservoir (35, 36, 47-49). In addition, most candidate LRAs did not 
significantly increase viral gene expression. The only LRAs that work as single agents are protein kinase C 
agonists (PKCs) like bryostatin-1, which is consistent with the role of PKC in signaling pathways downstream 
of T cell receptor engagement and co-stimulation (46). 
Other model systems of HIV-1 latency have be developed to test new intervention strategies, but 
none of these primary cell models fully recapitulates the complexities of the latent reservoir in vivo. Some of 
the most commonly used models include cell line models derived from immortalized T cell clones, primary 
cell models derived from HIV-1-negative donor CD4+ T cells, humanized mouse models generated by 
engraftment of mice with human tissues, and non-human primate models (50). Animal models are ideal for 
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study of HIV-1 latency in the setting of cART treatment. Simian immunodeficiency virus (SIV) and 
recombinant viral strains such as SHIV are the most commonly used strains in non- human macaque models 
of infection as the pathogenesis and the establishment of a latent reservoir are similar to HIV-1 pathogenesis 
in humans. Recently, several studies in non-human primate studies have demonstrated that a combination of 
toll-like-receptor 7(TLR7) agonist and broadly neutralizing antibodies could effectively delay viral rebound 
after the ART is stopped (51). PGT121 is a broadly neutralizing antibody that targets the V3 glycan site on the 
envelope and GS-9620 is a TLR7 agonist that stimulates TLRs on immune cells of the innate immune system. 
The most recent study included 11 rhesus macaques on cART infected with SHIV. After 2 years on cART, they 
received infusions of PGT121 and oral doses of GS-9620. Antiretroviral therapy was then discontinued 4 
months after the last doses of PGT121 and GS-9620. Of the 11 monkeys that received this combination of 
PGT121 and GS-9620, 6 experienced viral rebound and 5 continued to maintain undetectable viral load for at 
least 168 days after stopping cART. Even after viral rebound, monkeys that received the combination 
treatment had a lower viral load set point in lymph nodes, suggesting a decrease in the size of the latent 
reservoir (52). 
 So far, no single LRA or LRA combination has induced a substantial amount of viral reactivation, as 
measured by viral RNA production. The major caveat with this “shock and kill” strategy is that successful 
induction of viral expression does not guarantee that infected cells will die (53). Clearance of infected cells 
will require a second step involving a potent and efficient immune response. Other observations further 
complicate the “shock and kill” strategy include: insufficient number and function of HIV-specific CD8+ T cells 
and natural kill (NK) cells, disperse and scarce HIV antigen expression in latently infected cells, and the 
existence of viral populations evolved to escape CD8+ T cells killing (54-56) and escape from neutralizing 
antibodies.  A previous study demonstrated that latency reversal does not lead to reservoir reduction (57) 
Pre-stimulation of these HIV-specific CD8+ T cells with HIV peptides is required to increase the number and 
enhance the killing ability of these CD8+ T cells (58-60). Additionally, studies looking into the role of other 
effector cells, such as NK cells also suggested that “priming” of the effector cells is required to restore the 
function of the effector cells (61). Together, these results suggest that some level of vaccination may be 
necessary to activate the immune responses following viral reactivation for infected cell clearance.  
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In order to come up with an effective cure strategy, we need to obtain a better understanding of the 
latent reservoir. Previous studies looking into residual viremia in patients on cART have demonstrated that 
trace level of free virus in the plasma could not be reduced by treatment intensification or adding additional 
drugs. By sequencing the viruses in plasma, it has been shown that these viruses are continually released for 
years without sequence evolution in patients on cART (62, 63). These early studies indicate that the residual 
viremia arises from the daily activation of a small number of latently infected cells rather than from new 
cycles of replication. Interestingly, in most infected individuals, the residual viremia is dominated by a 
population of viruses with identical sequences (63). The clonal nature of the residual viremia suggests that it 
is produced by limited number of cells carrying identical HIV proviruses, which is likely to be a result of 
cellular proliferation. These results provided the first evidence for proliferation of latently infected cells, 
which copies the viral genome without error into progeny cells and contributes to HIV persistence. Several 
recent studies used HIV integration site analysis to provide definitive evidence for cellular proliferation of 
HIV-infected cells in individuals on cART (64, 65). These studies demonstrated that a large fraction of the 
infected cells have undergone clonal expansion based on the presence of identical HIV integration sites in 
different infected peripheral blood lymphocytes collected at different time points (64, 65). Interestingly, these 
studies showed that a significant amount of the expanded clones have proviruses integrated into genes 
related to cell growth and suggested that HIV integration into cancer-associated genes may promote 
proliferation of the infected cells (64, 65). One caveat with the integration site analysis is that the method 
captures only a small part of the HIV proviral genome. Therefore it is likely that many of the expanded 
cellular clones captured by this method carry defective proviruses. Other studies used the QVOA to recover 
independent infectious viruses in infected individuals and revealed that a large fraction of the latent reservoir 
is comprised of infected cells that have undergone clonal expansion (66-69). To study the mechanisms 
responsible for clonal expansion of cells containing replication-competent proviruses, we tested several 
conditions that have been proposed to induce clonal expansion of HIV-infected CD4+ T cells, including 
antigen stimulation and cytokine-driven homeostatic proliferation (69, 70). To confirm the importance of 
antigen-driven proliferation and homeostatic proliferation in HIV persistence, we also examined the in vivo 
dynamics of clonal populations of infected cells carrying intact proviruses and characterized the mechanisms 
that could induce in vivo proliferation of infected cells harboring replication-competent HIV.  
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The QVOA demonstrated the presence of HIV latent reservoir in all HIV infected individuals and 
longitudinal analysis demonstrated that the latent reservoir in resting memory CD4+ T cells undergoes slow 
decay in individuals on cART (27, 71). As discussed above, proliferation of infected cells carrying replication-
competent HIV is common (66, 68, 69). Therefore, the slow decay of the latent reservoir reflects a significant 
amount of proliferation of infected cells balanced by infected cell death. Studies that look into the dynamics of 
the latent reservoir provide insight into strategies that could dramatically reduce the size of the latent 
reservoir. Mathematical modeling suggested that even a 20% reduction in proliferation rate could effectively 
decrease the half-life of the latent reservoir. Therefore we should consider potential cure strategies that block 
proliferation of latently infected cells or speed up the decay of the latently infected cells. 
The QVOA allows quantification of replication-competent provirus, but it has recently been shown to 
underestimate the size of the latent reservoir because one single round of T cell activation does not efficiently 
induce all replication-competent proviruses (66). The standard QVOA can thus be considered a definitive 
minimal estimate for the size of the latent reservoir, capturing only a fraction of the latent reservoir with a 
single round of stimulation and outgrowth. To better understand the proviral landscape in infected 
individuals, several methods have been developed to capture the sequence of individual provirus to 
distinguish defective proviruses from those intact ones that are potentially capable of replication. The 
importance of such sequencing-based approaches is underscored by the surprising results of two recent 
studies that used a novel single genome amplification method to define the proviral landscape and examined 
the nature of defects present in persistent HIV proviruses (72, 73). Using the single proviral-genome 
sequencing method, we interrogated the sequences of the proviruses present in the QVOA culture wells that 
were negative for viral outgrowth. The vast majority of the proviruses were defective, harboring either large 
internal deletions and/or APOBEC3G-mediated hypermutation (72). Additionally, a follow-up study examined 
proviral genomes from HIV-infected individuals in resting CD4+ T cells. In all individuals studied, only a 
fraction of the proviruses are intact. Many of the proviral genomes in these individuals are hypermutated and 
deleted. Importantly, the median frequency of cells carrying intact proviruses is more than 60-fold higher 
than what is detected by the standard QVOA (73).  
A successful cure strategy would result in a drastic decrease in the size of the latent reservoir. 
Considering the low frequency of latently infected cell in infected individuals, an accurate and efficient 
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method is required for development and assessment of cure strategies. As discussed above, the QVOA gives 
us an absolute quantification of the minimal number of latently infected cells that can be induced to produce 
infectious virus with a single round of T cell activation. Multiple PCR-based methods have been developed to 
amplify sub-genomic regions and are used widely to measure the size of the reservoir (74, 75). The major 
caveat of these PCR-based methods is that they do not distinguish intact proviruses from defective 
proviruses, which are considered clinically irrelevant. Therefore PCR-based assays could lead to an 
overestimation in the size of the latent reservoir given that defective proviruses greatly outnumber intact 
proviruses in chronically treated individuals. In this thesis, I describe a novel digital droplet PCR based assay 
developed in our laboratory. The assay allows differential quantification of intact and defective proviruses 
and is used to measure the decay of different populations of proviruses. Using this intact proviral DNA assay 
(IPDA), I demonstrated that in most infected individuals, cells carrying intact proviruses undergo slow decay 
with a half-life close to that measured by the QVOA, while cells harboring defective proviruses showed 
greater variability that reflects proliferation or decline of these infected cells. I also examined the 
proliferative potential of cells carrying different types of proviruses using a microculture system. The results 
for in vitro proliferation of infected cells are consistent with our findings in vivo and provide insight into 
potential cure strategies for elimination of the latent reservoir.   
The Berlin patient case has renewed optimism that curing HIV-1 is possible and has inspired new 
cure approaches. In this thesis, I provide a detailed analysis of dynamics of persistent proviruses both in vivo 
and in vitro. I believe knowledge of latent reservoir dynamics will further our understanding of the virus and 






































The latent reservoir for HIV-1 in resting memory CD4+ T cells persists even in patients on optimal 
antiretroviral therapy (ART) and is the major barrier to cure  (23, 25, 76). The reservoir is established early 
in infection  (77, 78), and is extremely stable, with an estimated half-life of 44 months (6-8), making cure with 
ART alone unlikely. One strategy to eliminate the latent reservoir is termed shock-and-kill (9, 10). It depends 
on inducing proviral expression in latently infected cells to allow their elimination by immune mechanisms or 
viral cytopathic effects.  
Previous studies suggested that the proliferation of infected cells might contribute to HIV-1 
persistence (11-19). At least three mechanisms may explain the proliferation of infected cells: antigen-driven 
T cell proliferation (16), homeostatic proliferation (13), and proliferation driven by effects related to the site 
of HIV-1 integration (14, 15). Proliferation of infected cells driven by antigen or cytokines is unexpected 
because these stimuli also induce viral gene expression in latently infected cells (20, 21), which exposes the 
cells to viral cytopathic effects and immune clearance. In vivo, most productively infected cells have a short 
half-life (22, 23). Interestingly, it has been shown in a model system that latently infected CD4+ T cells can 
proliferate in response to cytokines such as IL-2 and IL-7 without viral reactivation  (79).  
Early evidence for the in vivo proliferation of HIV-1-infected cells came from detailed phylogenetic 
studies showing the presence in plasma of viruses with identical sequences termed ‘predominant plasma 
clones’ (PPCs) in some infected individuals on prolonged ART (11, 12). In treated patients who have 
suppression of viremia to below the limit of detection of clinical assays, this residual viremia can be detected 
with very sensitive assays (25-28). The residual viremia consists of archival viral sequences that are sensitive 
to the current drug regimen and that do not show evolution over time (12, 29-32). Numerous studies have 
shown that levels of residual viremia cannot be reduced by treatment intensification (33-35). All of these 
results suggest that residual viremia results from the daily activation of a small number of latently infected 
cells rather than ongoing cycles of replication. The clonal nature of residual viremia suggested that it is 
produced by limited subset of infected cells carrying identical HIV-1 sequences, likely arising as a result of 
cellular proliferation (11, 12).  
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Further support for the role of T cell proliferation in HIV-1 reservoir dynamics came from a landmark 
study that defined the distribution of latent HIV-1 among the central memory (TCM), transitional memory 
(TTM), and effector memory (TEM) CD4+ T cell subsets and the role of cytokine-driven homeostatic 
proliferation in reservoir stability (13).  
More recent studies used HIV-1 integration site analysis to provide direct and definitive evidence for 
clonal expansion in infected cells in individuals on long-term ART (14, 15, 36). A large fraction of the infected 
cells appear to have undergone clonal expansion based on the presence of identical HIV-1 integration sites in 
different infected peripheral blood lymphocytes (14, 15, 36). One study described identical viral sequences 
integrated at exactly the same position in the human genome in multiple cells, consistent with infected cell 
proliferation (15). Two studies suggested that HIV-1 integration into genes associated with cell growth and 
survival might drive proliferation of infected cells (14, 15).  
While clonal expansion of infected CD4+ T cells is prevalent in infected individuals, most HIV-1 
proviruses are defective (37, 38). Since integration site analysis captures only a small part of the HIV-1 
genome, it is likely that many of the expanded cellular clones detected by this method harbor defective 
proviruses (36). However, a highly expanded clonal population of CD4+ T cells harboring a replication-
competent provirus was recently characterized in an infected individual with metastatic squamous cell 
carcinoma, suggesting that cells carrying replication-competent proviruses can expand and persist (16). In 
addition, three recent studies demonstrated that clonal CD4+ T cell populations carrying replication-
competent viruses are common in infected individuals, accounting for over 50% of the latently infected cells 
examined (17-19). Therefore it is crucial to evaluate how cells containing replication-competent provirus 
proliferate. This information may help us to understand the forces that shape and preserve the latent 
reservoir.  
To address these issues, we asked whether infected CD4+ T cells harboring replication-competent 
provirus could proliferate in response to TCR stimulation or cytokines that are known to drive homeostatic 
proliferation and if so, whether this proliferation can occur without viral reactivation. In addition, we 
examined the in vivo dynamics of clonal populations of infected cells carry replication-competent HIV-1 to 




Materials and Methods 
Study subjects 
Participants were HIV-1–infected individuals who had suppression of viremia to less than 20 copies HIV-1 
RNA/ml on ART for more than 6 months. The Johns Hopkins Institutional Review Board approved this study, 
and written informed consent was obtained from all subjects. 
 
Resting CD4+ T cell isolation and plasma sample processing 
180 mL of blood was collected at each study visit using an acid-citrate-dextrose anticoagulant and processed 
as previously described (41). Briefly, plasma and cells were separated using a Ficoll density gradient. The 
plasma layer was quickly removed, centrifuged to remove any contaminating cells, and immediately frozen 
and stored at -80°C until further use. The buffy coat layer was subsequently removed, and resting CD4+
 
T cells 
were purified from total peripheral blood mononuclear cells (PBMC) via magnetic bead depletion as 
previously described (42). 
 
Cell culture conditions 
Approximately 10×106 cells were cultured untreated, or with anti-CD3/CD28 Dynabeads (25 µl/million cells, 
Thermo Fisher Scientific) + IL-2 (30 U/ml) or with IL-7 (10 ng/ml, BioLegend) + IL-2 (30 U/ml) in RPMI plus 
10% FBS for 7 days in the presence of tenofovir disoprixil fumarate (10 µM) and emtricitabine (10 µM). 
 
TCR sequencing 
Cell proliferating in response to anti-CD3/CD28 or IL-7 were sorted using Sony SH800 cell sorter based on 
CFSE dilution (see below). DNA was extracted from aliquots of resting CD4+ T cells and sorted cell populations 
(QIAGEN). Adaptive Biotechnologies performed TCR sequencing on extracted DNA.  
 
CFSE dilution and activation marker staining 
Total resting CD4+ T cells were stained with 5 µM CFSE (Life Technologies) before stimulation with anti-
CD3/CD28 or IL-7 as described above. The dilution of CFSE was analyzed 1 week later by flow cytometry on a 
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FACSCanto II cytometer (BD Biosciences). Unstimulated resting CD4+ T cells cultured for the same time 
period of time served as a negative control. Expression of activation markers was analyzed 1 week after initial 
stimulation. An aliquot of cells from each culture was stained with anti-CD25 (PerCP5.5), anti-CD69 (APC), 
and anti–HLA-DR (Pacific Blue) antibodies (BioLegend) at 4 °C for 15 min and analyzed by flow cytometry on 
the FACSCanto II cytometer.  
 
Quantitative Viral Outgrowth Assay (QVOA) 
The QVOA was performed on cultured, unsorted resting CD4+ T cells and on sorted cells that had proliferated 
in response to anti-CD3/CD28 or IL-7. The cells were plated at limiting dilution for viral outgrowth (200,000 
cells in 2 ml media per well) (37). Cells were activated with 0.5 µg/ml PHA and γ-irradiated allogeneic PBMCs 
from healthy donors (1). On day 2, media with PHA was removed and replaced with fresh media, and 
106 MOLT-4/CCR5+ cells were added to each well to allow expansion of virus released from cells in which 
latency had been reversed (42). MOLT-4/CCR5+ cells were obtained from the National Institutes of Health 
AIDS Reagent Program. CCR5 receptor expression on MOLT-4/CCR5+ cells was routinely tested by flow 
cytometry. On day 5, 0.75 ml media was removed and cells in each well were resuspended. Media was 
changed on days 5 and 9. A p24 ELISA (PerkinElmer) was performed on the supernatant on day 14 of the 
culture. Limiting dilution maximum likelihood statistics were used to calculate the frequency of latently 
infected cells (http://silicianolab.johnshopkins.edu/)  (80). 
 
RNA isolation, cDNA synthesis, and amplification of the env gene from proviruses in resting CD4+ T cells 
Viral RNA isolation was performed on 200 µl of the supernatant from each p24+ well using a ZR-96 Viral RNA 
kit (Zymo Research Corporation). Isolated RNA was treated with DNase (Thermo Fisher Scientific) and used 
for cDNA synthesis using the qScript cDNA Supermix kit (Quanta Biosciences). We then ran a nested PCR on 
cDNA from each p24+ well targeting the V3-V4 region of env. The nested PCR was performed using 500 ng 
cDNA and primers ES7 (5′-CTGTTAAATGGCAGTCTAGC-3′) and ES8 (5′-CACTTCTCCAATTGTCCCTCA-3′) for 
the outer reaction. The outer PCR products were then diluted 1:50, and 5 µl of this diluted outer PCR product 
was used for the inner PCR reaction with primers Nesty8 (5′-CATACATTGCTTTTCCTACT-3′) and DLoop (5′-
GTCTAGCAGAAGAAGAGG-3′). Primers were obtained from Integrated DNA Technologies. Detailed 
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amplification conditions were: 94C for 30 s, then 94C for 30 s, 55C for 30 s and 68C for 2 m for 39 cycles; 
then 68C for 5 m. PCR products were visualized on 1% agarose gels, and bands were extracted using the 
QIAquick Gel Extraction kit (QIAGEN). Extracted DNA was analyzed directly by Sanger sequencing at Genewiz, 
Inc. 
 
Amplification and sequencing of the env gene from plasma virus  
Free virus in the plasma of treated patients was analyzed as previously described (12).  Briefly, 6 mL aliquots 
of plasma were thawed and  ultracentrifuged at 170,000 × g for 30 minutes at 4°C. Pelleted virus was 
resuspended in 400 μL of phosphate buffered saline (PBS) (Invitrogen) and lysed, and the RNA extracted via a 
silica bead-based RNA isolation protocol, implemented on an EZ1 Biorobot (Qiagen). The RNA was eluted in 
60 μL of elution buffer and subsequently treated with amplification grade DNase I (Invitrogen), according to 
the manufacturer’s instructions. To amplify the C2-V4 region of the env gene from RNA isolated from free 
plasma virus, the RNA was subjected to a one-step reverse transcriptase (RT)-PCR using a Superscript III 
reverse transcriptase/Platinum Taq high fidelity DNA polymerase one-step RT-PCR kit (Invitrogen) followed 
by a nested PCR, using Platinum Taq high fidelity DNA polymerase, and 2.5 μL of the outer reaction as 
template. Control reactions were carried out for all experimental amplifications, including a no RT control to 
rule out DNA contamination and a no template control. Primers for the outer and nested reactions were as 
follows: (outer forward) 5' - CTGTTAAATGGCAGTCTAGC - 3', (outer reverse) 5' - CACTTC 
TCCAATTGTCCCTCA - 3', (nested forward) 5' -ACAATGCTAAAACCATAATAGT - 3', (nested reverse) 5' -
CATACATTGCTTTTCCTACT - 3'. PCR conditions for the one-step RT-PCR were as follows: reverse 
transcription at 50°C for 30 minutes, denaturation at 94°C for 3 minutes, followed by 40 cycles of 94°C for 30 
seconds, 55°C for 30 seconds, and 68°C for 1 minute. The PCR conditions for the nested reaction were as 
follows: denaturation at 94°C for 3 minutes, followed by 40 cycles of 94°C for 30 seconds, 55°C for 30 
seconds, and 68°C for 1 minute. Products of the nested reaction were separated on 1% agarose gels. Bands of 
appropriate size were excised, and the corresponding amplicons were eluted using QIAquick gel extraction 
kits (Qiagen). Isolated amplicons were subsequently cloned using a PCR2.1 TOPO cloning vector (Invitrogen), 
and at least 6 clones were sequenced from each PCR using an ABI Prism 3700 DNA analyzer 




A consensus sequence for each sample was generated with forward and reverse sequences using default 
assembly parameters on CodonCode Aligner software (CodonCode Corporation). Each consensus sequence 
was aligned with HXB2 reference HIV-1 sequence from the Los Alamos National Laboratory HIV sequence 
database using BioEdit software. Aligned sequences were trimmed to the same length for phylogenetic tree 
generation. Genetic distances were calculated, and neighbor-joining trees (81)were generated using a 
maximum composite likelihood algorithm and default parameters using MEGA7 software (82)(Molecular 
Evolutionary Genetics Analysis Program). The conclusions were not sensitive to the method of tree 
generation, and neighbor-joining trees are shown in the figures. 
 
Statistical analysis of clones  
A statistical test was designed to see if changes in the frequency distribution of clones carrying sequence-
identical replication-competent virus were significantly different between time points or if they could be 
attributed to sampling error alone. Under this null model, samples from two different time points are drawn 
from the same underlying distribution. Physiologically, this corresponds to a scenario in which the clonal 
composition of the latent reservoir does not change over time. In order to construct a null distribution of data 
for this model, data from two time points were aggregated and re-partitioned randomly while all margins 
were fixed (implemented using the R package vegan, Oksanen et al.). To test whether the observed data 
supported a more extreme difference in proportions than the re-partitioned data, the likelihood ratio test 
statistic was calculated for the observed data and the distribution of re-partitioned data under a multinomial 
model. The likelihood ratio test statistic T was derived by finding the maximum likelihood parameter 
estimate vector ?̂? for a multinomial model with the combined clone size data (n1+2) and a multinomial model 







P-values correspond to the proportion of random partitions with statistic T were at least as large as that of 
the true observation. This test is equivalent to a Fisher’s exact test when the permuted matrices are ordered 




CD4+ T cells containing replication-competent virus can proliferate in response to T cell receptor (TCR) 
activation and cytokine treatment 
The immune system maintains normal levels of T cells in part through a process of homeostatic 
proliferation. For CD4+ T cells, the γc-cytokine IL-7 is an important stimulus for homeostatic proliferation in 
vivo (39, 40). A previous study evaluated the role of IL-7-driven proliferation in HIV-1 reservoir stability and 
demonstrated relationship between plasma IL-7 concentration and reservoir size (13). Bosque et al. used a 
primary cell model of HIV-1 latency to demonstrate that latently infected central memory T cells could 
proliferate in the presence of IL-7 without viral reactivation (24). To explore the stimuli and conditions 
associated with proliferation of infected cells in vivo, we purified resting CD4+ T cells from 10 HIV-1-infected 
donors on ART and stained the cells with carboxyfluorescein succinimidyl ester (CFSE) dye. The cells were 
then treated with anti-CD3/CD28 antibodies or with an optimal concentration of IL-7 (79)for 7 days in the 
presence of antiretroviral drugs (Figure 1 a). IL-2 was included in all of the cultures to maintain cell viability 
and match the conditions described by Bosque et al. (24). Most cells proliferated in response to anti-
CD3/CD28 antibodies, while proliferation induced by IL-7 was more limited (Figure 1 b). We also examined 
the activation status of cells cultured for 7 days with anti-CD3/CD28 or IL-7 by flow cytometry. Cells were 
stained for CD69, CD25 and HLA-DR. With anti-CD3/CD28 stimulation, most cells were positive for CD25, 
while only 20% of the cells treated with IL-7 were positive for CD25 (Figure 1 b). 
The cells receiving each stimulus were then sorted based on whether they had proliferated in 
response to anti-CD3/CD28 or IL-7. This allowed us to examine the properties and fate of infected cells that 
had recently gone through the cell cycle.  We sequenced the T cell receptors (TCRs) in the sorted CFSE low 
cell populations that proliferated in response to each treatment and compared the sequences to those in the 
resting T cell population. With anti-CD3/CD28 stimulation, the proportions of cells with particular TCRs 
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remained the same as in unstimulated resting CD4+ T cells (P>0.001), while some clones achieved a higher 
frequency in the population that proliferated in response to IL-7 compared to that in unstimulated resting 
CD4+ T cells (P<0.001) (Figure 1 c). To explore the non-uniform expansion induced by IL-7, we then analyzed 
IL-7 receptor (CD127) expression on resting CD4+ T cells from infected individuals and found that 90% of the 
cells expressed CD127 (Figure 1 d). This observation indicates that not all resting CD4+ T cells are able to 
proliferate in response to cytokines, which may provide a partial explanation for the preferential expansion of 
certain clones in response to IL-7 (Figure 1 c). In any event, the sorting of cells that had proliferated in 
response to anti-CD3/CD28 or IL-7 allowed us to directly examine the clonal expansion of HIV-1-infected 
cells. 
We next asked whether either stimulation induced rapid virus release from freshly isolated resting 
CD4+ T cells. We collected culture supernatants from resting CD4+ T cells from 10 infected individuals after 7 
days of stimulation with media alone, anti-CD3/CD28, or IL-7. Anti-CD3/CD28 induced virus production, as 
measured by HIV-1 mRNA in the supernatants. IL-7 treatment induced detectable HIV-1 mRNA in the 
supernatant of cells from 5 out of 10 infected individuals but the HIV-1 mRNA levels for those patients were 
at least 2 logs lower than those observed with anti-CD3/CD28 (Figure 1 e). The finding that latently infected 
CD4+ T cells treated with IL-7 can proliferate with little or no virus production suggests that homeostatic 
proliferation induced by cytokines could potentially expand the latent reservoir without exposing the 
infected cells to immune clearance. Anti-CD3/CD28 induced much higher levels of T cell proliferation and 
latency reversal.   
Most infected cells harbor defective proviruses that may not interfere with clonal expansion (37, 38). 
To determine whether cells harboring replication-competent HIV-1 genomes can proliferate in response to 
these stimuli, we plated the sorted cells that had proliferated in response to anti-CD3/CD28 or IL-7 in a 
limiting dilution quantitative viral outgrowth assay (QVOA) (Figure 1 a). In this assay, the cells are stimulated 
with PHA and γ-irradiated allogeneic peripheral blood mononuclear cells (PBMC) to reverse latency as 
previously described (41, 42). Infectious virus particles released following reversal of latency are detected by 
adding MOLT4/CCR5+ cells to the culture. These cells lack class II MHC expression and do not cause 
allogeneic stimulation of patient cells (42). However, they are highly susceptible to infection and allow 
exponential growth of infectious virus released from patient cells. With this assay, we detected viral 
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outgrowth by p24 ELISA assay of supernatants from cultures of unstimulated resting CD4+ T cells or cell 
populations that had proliferated in response to stimulation with either anti-CD3/CD28 or IL-7 (Figure 1f). 
The frequencies of cells that were able to produce replication-competent virus were similar in all three cases 
(Figure 1 f). Thus cells harboring replication-competent virus can proliferate in response to either TCR 
stimulation or cytokines, survive for at least 7 days, and retain the ability to produce infectious virus upon 
subsequent stimulation.  
In the same experiment, cell populations that had proliferated in response to either anti-CD3/CD28 
stimulation or cytokine treatment were also plated in the QVOA without additional PHA stimulation. Viral 
outgrowth was observed in cultures set up with MOLT-4 cells and cells that had proliferated in response to 
anti-CD3/CD28 without another round of PHA activation, suggesting that CD4+ T cells carrying replication-
competent provirus can proliferate with anti-CD3/CD28 stimulation and continue to produce virus for at 
least 7 days. However, no viral outgrowth was observed in cultures set up with cells that had proliferated in 
response to IL-7 unless PHA and irradiated allogeneic PBMC cells were added (Figure 1 f). This result 
suggests that the concentrations of cytokines used in this culture assay were sufficient to induce proliferation 
of some resting CD4+ T cells without latency reversal. The progeny cells could produce virus with additional 
stimulation. We have previously shown that CD4+ T cells harboring replication-competent provirus can 
proliferate in response to global T cell activation without producing virus while retaining the ability to do so 
upon subsequent stimulation (18, 37). Thus both antigen and cytokines provide a potential explanation for 






Figure 1: Proliferation of infected cells in response to TCR stimulation and cytokines. (A) Experimental setup 
with assay time course. Resting CD4+ T cells wereisolated from participants on ART; stained with CFSE; and 
then cultured for 7 d with media alone, cultured with anti-CD3/CD28, or treated with IL-7. On day 7,cells that 
had proliferated in response to anti-CD3/CD28 or IL-7 were isolated based on CFSE dilution. Half of the 
sorted cells were then plated in a limiting dilution QVOA with PHA and irradiated allogeneic PBMCs. The 
other half of the cells were plated at the same dilutions without PHA or irradiated allogeneic PBMCs. After 24 
h, PHA was removed and MOLT-4/CCR5+ cells were added to all culture wells to expand virus released from 
infected cells. On day 20, a p24 ELISA was performed to quantify viral outgrowth. Cells treated with media 
alone were cultured without sorting.  
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(B) Activation marker expression and proliferation induced by anti-CD3/CD28 and IL-7 stimulations. Resting 
CD4+ T cells were stained with CFSE before stimulation. CFSE dilution and activation marker expression were 
quantitated by flow cytometry 7 d after stimulation.  
(C) TCR sequence analysis. TCRs of cells that proliferated with anti-CD3/CD28 stimulation or IL-7 stimulation 
were sequenced, and the percentage of each TCR was then calculated in each sample.  
(D) Resting CD4+ T cell expression of IL-7 receptor (CD127). Freshly isolated resting CD4+ T cells were 
stained with CD127 to quantify IL-7 receptor expression level before any treatment.  
(E) Induction of virus production by anti-CD3/CD28 and IL-7. Resting CD4+ T cells from individuals on ART 
(n = 10) were left untreated or simulated with anti-CD3/CD28 or IL-7 for 7 d. HIV-1 RNA levels in culture 
supernatants were measured by qRT-PCR. **P < 0.01. L.O.D., limit of detection; NS, P > 0.05.  
(F) Frequency of latently infected cells that proliferated in response to anti-CD3/CD28 or IL-7 as measured by 
QVOA. Sorted cells were analyzed by QVOA with or without an activating stimulus (PHA and allogeneic 
PBMCs). The frequency of cells producing replication-competent virus was determined by limiting dilution 




Some expanded clones harboring replication-competent virus persist overtime while others wax and wane 
Three recent studies showed that expanded cellular clones containing replication-competent HIV-1 
are common in infected individuals (17-19). However little is known about the dynamics of these clonal 
populations. To examine whether these clones persist, we recovered the infectious virus from 8 treated 
individuals at 2 or 3 time points spanning 2 to 3 years (Figure 2 a). Limiting dilutions of resting CD4+ T cells 
were subjected to stimulation in the QVOA with the T cell mitogen PHA and γ-irradiated allogeneic PBMC. 
MOLT-4/CCR5+ cells were added on day 2 of the culture to expand virus released from cells in which latency 
was reversed, and the culture supernatants were tested for virus production by p24 ELISA on day 14 (42). We 
amplified the highly variable V3-V4 region of the env gene by RT-PCR from viral RNA in the supernatants of 
all p24+ wells from the QVOA. As expected from the limiting dilution format of the QVOA, sequences from 
individual p24+ wells should represent independent isolates of replication-competent virus. Sequences from 
each individual were compared by phylogenetic analysis. All 8 individuals had one or more sets of 
independent isolates with identical env sequences at 2 or 3 time points (Figure 2 a). To determine whether 
these isolates with identical env sequences were identical throughout the genome, a previously described 
clonal prediction score was used  (83). The env amplicon had a clonal prediction score of 96, indicating that 
96% of the sequences identical in this region are identical throughout the entire HIV-1 genome. In addition, 
we previously established using full genome sequencing that a subset of these sequences obtained at the first 
time point were identical throughout the entire HIV-1 genome (Figure 2 a) (18). Phylogenetic analysis 
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established that identical proviruses in these patients reflect expanded cellular clones rather than infection of 
a large number of cells by a dominant viral species (18). Therefore each set of identical env sequences is very 
likely to represent a clonal population of infected cells derived from a single initially infected cell by extensive 
in vivo proliferation.  
Longitudinal sampling over a 1-3 year time span allowed us to address the question of whether 
clones harboring replication-competent virus persist over time. In 7 out of 8 individuals, we observed 
sequences that were present and prevalent at one time point at other time points (Figure 2 a, b), suggesting 
some cellular clones persisted on a time scale of years and comprised a substantial fraction of the total 
population of resting CD4+ T cells with replication competent proviruses over these time periods. However, in 
7 out of 8 individuals, we also found clonal populations carrying different replication-competent viruses at 
time point 2 and time point 3 that were not present at time point 1 (Figure 2 a, b). In addition to the 
appearance of new clones, we also observed the disappearance of other clones. In subject S01, one large 
expanded clone was only observed at time point 1 and then disappeared, while another expanded clone 
appeared and was only seen at time point 2 (Figure 2 a, b). The same dramatic appearance and disappearance 
pattern was observed in subject S04 (Figure 2 a, b). Of all the sequences collected, 65.6% were seen only at 
one time point. Of 17 clones observed at two or more time points, 10 clones showed an increasing frequency 
over time while 7 clones decreased in frequency over time.  Overall these results are consistent with a 
homeostatic processes in which individual clones increase and decrease in frequency while the size of the 
total pool of latently infected cells decreases only very slowly (1, 7, 8). Due to the low frequency of cells 
harboring inducible replication-competent proviruses, the number of infected cells sampled at any given time 
point is limited.  We therefore analyzed whether a difference in observed clone frequencies between time 
points within the same patient could be attributed to sampling error alone (Figure 2b). In most comparisons 
between pairs of time-points, the observed difference in clone frequencies was highly significant, supporting 
the notion that the difference in clone frequencies cannot be accounted for by sampling alone (Figure 2b). 
These findings demonstrate that clonally expanded cells harboring replication-competent virus wax and 
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Fig. 2. Expanded clones carrying replication-competent HIV-1 emerge and wane over time.  
(A) Phylogenetic trees of env sequences of independent isolates of replication-competent virus from eight 
subjects on ART (S01–S08) are shown. Sequencing was performed on genomic viral RNA in supernatants of 
p24+ wells. Different colors correspond to viruses recovered from different time points as indicated under 
the time line. Groups of identical sequences are indicated by symbols present on the same vertical “rake.” 
Sequences for the first time point were included in a previous study (18). Sequences that were previously 
shown to be identical by full-genome sequencing are grouped in boxes (18). The time scale indicates time in 
years from study entry. All patients were on suppressive ART for >6 mo before study entry. Black squares 
indicate the reference sequence HXB2.  
(B) Dynamics of expanded clones containing replicationcompetent HIV-1. Each pie figure shows how all of the 
replication-competent viruses (n) collected at a specific time point (shown on the x axis) are divided into 
clonal populations, with distinct colors representing different clones. Clones marked by M were identified at 
multiple time points. Starred lines indicate samples that are significantly different according to a test for 
difference in clone proportions when the null model is a random partition of the aggregated samples 




Clonal populations of free plasma virus change overtime 
To provide further insight into the dynamics of expanded cellular clones carrying replication-
competent HIV-1, we analyzed residual viremia in patients on suppressive ART over time. Most of the defects 
found in HIV-1 proviruses are major defects that would preclude the production of virus particles (37, 38, 
44).  Therefore, the dynamics of the cells that produce the residual viremia are likely to reflect the dynamics 
of cells that carry replication-competent proviruses. However, analysis of residual viremia provides 
additional information because virus production requires latency reversal. 
Figure 3 shows phylogenetic analysis of env gene sequences from plasma virus and from proviruses 
in resting CD4+ T cells from a representative patient on ART. This phylogenetic tree illustrates previously 
described features of residual viremia, including an intermingling of plasma and cellular sequences (12), the 
lack of temporal structure (degree of divergence is not correlated with time of sampling) (45), the presence of 
predominant plasma clones (PPC) (12), and a lack of correlation between the frequency of clonal sequences 
in plasma and resting CD4+ T cells (12). All of these features are consistent with the hypothesis that a stable 
reservoir of HIV-1 in resting CD4+ T cells contributes to the residual viremia as cells in the reservoir become 
activated. One large clonal population was detected at time point 1 and persisted through time point 3 five 
months later, but very few matching proviral sequences were found. The lack of correlation between the 
frequency of clonal sequences in plasma and resting CD4+ T cells reflects the fact that most of the proviruses 
 26 
in resting CD4+ T cells are defective and incapable of producing plasma virus (37, 38). Therefore extensive 
sampling is required to find the matching proviral sequences. The presence of a large clonal population in 
plasma reflects not only the proliferation of a clone of infected cells but also the activation of at least some of 
those cells, presumably by some antigen, to a degree that reverses latency. 
In 4 of 8 patients sampled, we found dominant plasma virus populations as evidenced by the 
identical viral sequences obtained in multiple independent single genome amplifications. Interestingly, we 
observed the same pattern of appearance and disappearance of these plasma virus clones as we observed 
with proviruses in resting CD4+ T cells (Figure 4 a). Subject 14 was studied at 4 time points over a 2-year 
period. We identified one large clonal population that was first detected at time point 2, became dominant at 
time point 3, and persisted though time point 4, 1.2 years later (Figure 4 a, 5). Another distinct clonal 
population was dominant at time point 2 but was not seen in the plasma at later time points. Another distinct 
clonal population of plasma virus was identified only at the last time point in this patient. This study 
participant also had populations of clonal proviruses from resting CD4+ T cells. However we only found 
matching proviral sequences for one of the clonal plasma viruses (Figure 4 a), consistent with the fact that the 
vast majority of proviral sequences are defective. These results show that clonal populations of infected cells 
producing residual viremia wax and wane on a time scale of years. This likely reflects changes in the 
frequency of individual clones, as indicated by viral outgrowth studies (Figure 2). This in turn may reflect 
changes in the exposure to cognate antigens that could drive both proliferation and virus production. 
In subject 13, we sampled plasma viruses at 4 points over a 4-year period (Figure 4 b, 5). We 
observed multiple distinct clonal populations of plasma viruses, the abundance of which changed over time. 
In subject 15, we sampled plasma viruses at 6 time points over a 4-year period (Figure 4 b). Three distinct 
clonal populations of plasma viruses were identified. Two populations were observed at earlier time points 
but not after the 3rd time point. Another population was only observed at time point 5 and time point 6 
(Figure 4 b, 5). The pattern of emergence and disappearance of clonal populations of plasma virus is 
summarized in Figure 5. This pattern is consistent with our finding that clonal populations of replication-
competent provirus wax and wane overtime and supports a model of release of virus from clonally expanded 




Fig. 3. Neighbor-joining phylogenetic tree constructed with env sequences from the plasma and resting CD4+ 
T cells from subject S16. Samples were taken at the indicated times after study entry while the plasma HIV-1 
RNA level was <50 copies per milliliter. Samples were processed for analysis of HIV-1 RNA in plasma 
(triangles) and proviral DNA in resting CD4+ T cells (circles). 
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Fig. 4. Plasma virus clones wax and wane over a time scale of years. Neighbor-joining phylogenetic trees 
constructed with env sequences from the plasma (triangles) and resting CD4+ T cells (circles) from subjects 
S14, S13, and S15. Samples were taken at the indicated times after study entry while the plasma HIV-1 RNA 
level was <50 copies per milliliter.  
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Fig. 5. Composite graph illustrating the appearance and longevity of clonal populations of free plasma virus 
and provirus derived from resting CD4+ T cells. Colors correspond to time of sampling and are derived 
directly from the corresponding phylogenies. 
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The stable latent reservoir for HIV-1 in resting CD4+ T cells is a major barrier to cure (1). 
Proliferation of infected cells could explain the stability of the latent reservoir.  However, some mechanisms 
that drive proliferation of infected cells also induce proviral expression so that infected cells can be 
eliminated by immune mechanisms or die from viral cytopathic effects (20, 21). Despite the fact that 
productively infected cells have a very short half-life  (84, 85), accumulating evidence suggests that infected 
cells harboring replication-competent virus can undergo clonal expansion in vivo (16). Sequencing of plasma 
virus in subjects on ART provided additional evidence for clonal expansion of cells carrying replication-
competent virus, as residual viremia is often dominated by identical viral sequences (11, 12). There is great 
current interest in understanding the stimuli driving clonal expansion. 
Studies in a model system suggested that infected cells can proliferate in response to IL-7 and IL-2 
without viral reactivation  (79). Therefore, we examined into whether infected cells carrying replication-
competent virus from patients on ART could expand through cytokine-driven homeostatic proliferation and 
whether clonally expanded populations persist overtime in vivo. We demonstrate here using patient samples 
that infected cells harboring replication-competent HIV-1 can proliferate through TCR or cytokine-driven 
mechanisms. We show that cells carrying replication-competent HIV-1 can proliferate in response to cytokine 
treatment and do so without producing infectious virus while retaining the ability to produce virus following 
a subsequent stimulation. It is worth noting that the level of proliferation induced by cytokine treatment is 
related to IL-7 receptor expression. IL-7 receptor α chain CD127 is expressed at higher levels in central 
memory and transitional memory CD4+ T cells but not in effector memory CD4+ T cells (39, 46). We have 
previously shown that latently infected cells carrying replication-competent proviruses can also proliferate in 
response to mitogen stimulation without producing virus  (66). These findings are consistent with the 
observation of clonal expansion in vivo and help explain the large number of latently infected cells carrying 
identical intact viral sequences (18).   
Although it is clear that the latent reservoir is dominated by clonal populations of infected CD4+ T 
cells, the dynamics of these populations have been unclear and could differ from those of clonal populations 
of infected cells carrying defective proviruses. We show here that some clonal populations of resting CD4+ T 
cells carrying replication-competent HIV-1 wax and wane in vivo on a time scale of years, while others persist 
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over the time period examined. We also demonstrate that clonal populations of plasma viruses emerge and 
disappear on a time scale of years in participants on ART. The observations on plasma virus suggest are 
consistent with the presence of expanded cellular clones and show that at least a fraction of the cells are 
constantly activated to produce virus. The waxing and waning of predominant plasma viral populations is 
likely a reflection of the underlying proliferative mechanisms that maintain the latent reservoir as well as 
changes in the stimuli that drive infected cells to produce virus.  
Overall, these results support the hypothesis that the latent reservoir is maintained by clonal 
proliferation. This is important, as eradication of HIV-1 infection necessitates elimination cells carrying 
replication-competent latent proviruses, and the potential of these cells to undergo enormous clonal 
expansions makes eradication more challenging. Therefore it is important to determine the mechanisms 
responsible for clonal expansion of cells carrying replication-competent proviruses. The observation that 
expanded clones wax and wane overtime suggests that proliferation of infected cells is balanced by a 
significant amount of cell loss. The dynamic changes support antigen and cytokines as potential drivers of 
clonal expansion, but they do not support a cell autonomous proliferation driven by effects related to the site 












































A stable latent reservoir for HIV-1 in resting CD4+ T-cells precludes cure  (23, 25, 76). Early studies 
of infected donors on suppressive ART demonstrated that a subset of these cells carrying replication-
competent HIV-1 could be induced to replicate in tissue culture, comprising what we now consider the latent 
reservoir. However subsequent studies have revealed that a complex population of both replication-
competent proviruses and defective proviruses coexist in every infected individual. Curative strategies 
targeting the reservoir are being tested  (74, 75, 86) and require accurate, scalable reservoir assays. The 
development of assays that measure HIV-1 persistence has been invaluable in furthering our understanding 
of the impact of ART on viral replication and the nature of the latent reservoir. However, current methods 
have several limitations and the quantification of the latent reservoir remains challenging. The reservoir was 
defined with quantitative viral outgrowth assays (QVOAs) for cells releasing infectious virus following one 
round of T-cell activation (86). However, QVOAs and newer assays for cells producing viral RNA or virions 
may underestimate reservoir size because studies have demonstrated that additional proviruses are induced 
following more rounds of activation (66). QVOA allows quantification of replication-competent proviruses, 
but it is labor and time consuming, which makes them impractical for large cohort studies. Given the 
complexity of the QVOA, most studies rely on PCR-based assays to detect proviral DNA regardless of 
transcriptional status. PCR-based assays that measure HIV-1 DNA have a higher throughput, but the clinical 
relevance of these assays is unclear, as these PCR-based assays would miss proviral defects outside of the 
region amplified. Given that defective proviruses greatly outnumber intact proviruses in most chronically 
treated individuals, these PCR-based assays could overestimate the size of the latent reservoir. Additionally, 
infected cells carrying intact versus defective proviruses may respond differently to a given intervention. 
Therefore, total HIV-1 DNA data could be misleading.  
We describe a novel approach that separately quantifies intact and defective proviruses and show 
that the dynamics of cells carrying intact and defective proviruses are different in vitro and in vivo, a finding 





Materials and Methods 
 
Study participants 
Characteristics of study participants are given in Table 1. The Johns Hopkins Institutional Review Board and 
the UCSF Committee on Human Research approved this study. All participants provided written consent prior 
to enrollment. Except where indicated, participants were HIV-1 infected adults on suppressive ART with 
undetectable plasma HIV-1 RNA levels (< 50 copies per mL) for >6 months. Chronic phase (CP)-treated 
subjects are defined as subjects starting ART >180 days from the estimated date of infection. Acute phase 
(AP)-treated subjects started ART < 100 days after the estimated date of infection. For longitudinal analysis, 
additional peripheral blood mononuclear cell (PBMC) samples were obtained from 10 HIV-1-infected men 
followed in the Baltimore-Washington DC center of the Multicenter AIDS Cohort Study (MACS) (87) who had 
undetectable plasma HIV RNA (<20 copies/ml by Roche Taqman assay) at all semiannual study visits for 5 
years or more, with no blips or missed visits. PBMC cryopreserved at visits at least 5 years apart, and viably 
stored as per MACS protocols, were studied. Characteristics of these 10 men are given in Table 1 (CP31-
CP49). 
 
CD4+ T-cell isolation 
Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation using Ficoll-Paque PLUS 
(GE Healthcare Life Sciences; Marlborough, MA) per manufacturer’s instructions. Untouched total CD4+ T-
cells were then enriched from PBMC using negative immunomagnetic selection via the EasySep Human CD4+ 
T Cell Enrichment Kit (StemCell Technologies; Vancouver, BC). In some experiments, resting CD4+ T-cells 
(CD4+, CD69–, CD25– and HLA-DR–) were isolated using a second negative selection step (CD25-Biotin; Anti-
Biotin MicroBeads; CD69 MicroBead Kit II; Anti–HLA-DR MicroBeads, all from Miltenyi Biotec). Resting CD4+ 
T-cell purity was consistently >95% as assessed using flow cytometry. 
 
Bioinformatic analysis 
We constructed an alignment of 431 published (73, 88) full length proviral sequences obtained from 28 HIV-
1-infected adults by single genome analysis. Of these individuals, 19 started suppressive ART during chronic 
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infection while 9 started suppressive ART during acute infection. 24 had prolonged suppression of viremia 
(>6 months) when studied, and 5 were viremic when studied (one individual was studied at two time points, 
before and after ART). Clinical characteristics of these individuals are given in the relevant publications (73, 
88). The proportion of different types of defects in HIV-1 proviruses varies with the stage of disease at which 
ART is started and the level of viremia (73). For most analyses, we used sequences from patients who 
initiated ART during chronic infection and who had sustained suppression of viremia to below 50 copies HIV-
1 RNA/ml of plasma for >6 months. These sequences (n=211) are thus representative of the most common 
group of infected individuals who would be eligible for cure interventions. For analyses of specific type of 
defects, we used all sequences in the database with that defect. For examples, for analysis of hypermutation, 
we used all database sequences with hypermutation (n=100) and additional hypermutated sequences 
obtained by single genome env sequencing. Hypermutation in the GG or GA context was confirmed using the 
Hypermut algorithm (89). Positions of primers for ddPCR analysis were evaluated using a sliding window 
analysis of two hypothetical 100 bp amplicons, scoring for lack of significant overlap (>5%) with mapped 
deletions in the database sequences with deletions. Sequence conservation was evaluated using separate 
alignments of US clade B sequences from the Los Alamos HIV sequence database. 
 
Intact proviral DNA assay (IPDA) 
A variety of experimental conditions were used in the development of the IPDA. The following is an optimized 
recommended procedure. In general, the IPDA is performed on DNA from 5x106 CD4+ T-cells. Genomic DNA 
is extracted using the QIAamp DNA Mini Kit (Qiagen; Hilden, Germany) with precautions to avoid excess DNA 
fragmentation. DNA concentrations are determined using the Qubit3.0 and Qubit dsDNA BR Assay Kit 
(ThermoFisher Scientific; Waltham, MA). Quantification of intact, 5’ deleted, and 3’ deleted and/or 
hypermutated proviruses are carried out using primer/probe combinations optimized for subtype B HIV-1 
(Table 3). A qualified research use only (RUO) version of the primer/probe mix is available from Accelevir 
Diagnostics, Baltimore, MD (HIV-1 Proviral Discrimination 20x primer/probe mix). The primer/probe mix is 
comprised of oligonucleotides for two independent hydrolysis probe reactions that interrogate conserved 
regions of the HIV-1 genome to discriminate intact from defective proviruses. HIV-1 Reaction A targets the 
packaging signal (Ψ) which is a frequent site of small deletion and is included in many large deletions in the 
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proviral genome. The Ψ amplicon is positioned at HXB2 coordinates 692-797. This reaction utilizes forward 
and reverse primers, as well as a 5’ 6-FAM labelled hydrolysis probe. Successful amplification of HIV-1 
Reaction A produces a FAM fluorescence in droplets containing Ψ, detectable in channel 1 of the droplet 
reader. HIV-1 Reaction B targets the Rev-Response Element (RRE) of the proviral genome, with the amplicon 
positioned at HXB2 coordinates 7736- 7851. This reaction utilizes forward and reverse primers, as well as 
two hydrolysis probes: a 5’ VIC labelled probe specific for wild-type proviral sequences and a 5’ unlabeled 
probe specific for APOBEC-3G hypermutated proviral sequences. Successful amplification of HIV-1 
Reaction B produces a VIC fluorescence in droplets containing a wild-type form of RRE, detectable in channel 
2 of the droplet reader, while droplets containing a hypermutated form of RRE are not fluorescent. Droplets 
containing HIV-1 proviruses are scored as follows. Droplets positive for FAM fluorescence only, which arise 
from Ψ amplification, score as containing 3′ defective proviruses, with the defect attributable to either 
APOBEC-3G-mediated hypermutation or 3′ deletion. Droplets positive for VIC fluorescence only, which arise 
from wild-type RRE amplification, score as containing 5′ defective proviruses, with the defect attributable to 
5′ deletion. Droplets positive for both FAM and VIC fluorescence score as containing intact proviruses (Fig. 
8a.b). An important aspect of the quantitation of intact proviruses is correction for DNA shearing between 
amplicons that artificially reduces Q2 droplets while increasing Q1 and Q4 droplets (Fig. 8b). This can be 
done accurately through ddPCR analysis of a host gene, which also provides a measure of input cell number. 
In principle, any host gene can be used, with two ddPCR amplicons spaced at the same distance as the HIV-1 
amplicons described above. As demonstrated in Fig. 3d and 3e, this approach allows for accurate correction 
for DNA shearing. Simultaneous quantification of DNA shearing and input human genome equivalents is 
performed using another aliquot of the same DNA sample. For the studies described here, oligonucleotides 
for two independent hydrolysis probe reactions that interrogate the human RPP30 gene (Chr.10: 90,880,081 
on GRCh38) were used. A qualified RUO RPP30 primer/probe mix is available from Accelevir Diagnostics, 
Baltimore, MD (DNA Shearing + Copy Reference 20x primer/probe mix). In this primer/mix, the total distance 
between duplex reactions and individual amplicon sizes are equivalent to those of the HIV-1 proviral 
discrimination reactions described above. Optimal reaction melting temperatures are equivalent for all 
reactions. Comprehensive oligonucleotide analysis predicted no potential off-target nucleotide binding or 
amplification (BLASTn) and no self-dimerization, hetero-dimerization, or primer hairpin formation. RPP30 
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Reaction A employs a 5’ 6-FAM labelled hydrolysis probe, and RPP30 Reaction B employs a 5’ HEX labelled 
hydrolysis probe. Droplets positive for both 6-FAM and HEX fluorescence score as containing an unsheared 
RPP30 gene fragment, while droplets positive for only a single fluorescence score as containing part of a 
sheared RPP30 gene fragment. The ratio of dual fluorescent to single fluorescent droplets is used to calculate 
a DNA Shearing Index (DSI), and this index is applied to both genome copy number input reactions and HIV-1 
proviral discrimination reactions to correct for experimentally observed DNA shearing. Droplet digital PCR 
was performed on the Bio-Rad QX200 AutoDG Digital Droplet PCR system using the appropriate 
manufacturer supplied consumables and the ddPCR Supermix for probes (no dUTPS) (Bio-Rad Laboratories; 
Hercules, CA). For HIV-1 proviral discrimination reactions, 700 ng of genomic DNA was analyzed in each 
reaction well. For DNA shearing and copy number reference reactions, 7 ng of genomic DNA was analyzed in 
each reaction well. Multiple replicate wells were performed for each reaction type to ensure consistent 
quantitation, and replicate wells were merged during analysis to increase IPDA dynamic range. The following 
thermal cycling program was used for all reactions, with a 2 C ramp rate: enzyme activation at 95 °C for 10 
min; 45 cycles at 94 °C for 30s and 59 °C for 1min; 98°C for 10min; and then infinite hold at 4 °C. In general, 
parallel processing and analysis of uninfected donor CD4+ T-cells was performed for each IPDA run as a 
negative control while qualified JLat6.3 genomic DNA was analyzed in each IPDA run as a positive control. 
After correction for DNA shearing, data is expressed as proviral copies per 106 CD4+ T-cells. 
 
Cell Lines 
The J-Lat Full Length Clone (clone #6.3) from Dr. Eric Verdin was obtained through the NIH AIDS Reagent 
Program, Division of AIDS, NIAID, NIH. 
 
Clonal microcultures 
Purified resting CD4+ T-cells from HIV-1-infected donors on suppressive ART were analyzed for proviral DNA 
copies using gag qPCR as previously described23. The resulting values were corrected for gag- proviruses, 
and cells were plated at approximately one infected cell per well (2000-4000 total resting CD4+ T-cells) in 
96-well plates. The cells were then stimulated with anti-CD3/CD28 Dynabeads (25 μl per million cells; 
Thermo Fisher Scientific) in RPMI containing 10% fetal bovine serum and 100 U/mL IL-2 (Novartis) for 7 
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days in the presence of tenofovir disoproxil fumarate (10 μM) and emtricitabine (10 μM). Half of the media in 
each well was removed and replaced with fresh media, anti-CD3/CD28 Dynabeads and antiretroviral drugs 
weekly for 2-3 weeks. DNA isolation was performed on cells from each well using a Quick-DNA 96 Kit (Zymo 
Research Corporation). 1/4th of the extracted DNA was analyzed by the IPDA to determine the type of 
provirus and proviral copy number in each well. The remaining DNA was used for integration site analysis 
and full genome sequencing. 
 
Integration site analysis  
Integration site analysis was performed on cell clones obtained from clonal microcultures using previously 
described linker ligation method (90-92). Sites for which both the 5ʹ and 3ʹ junctions were captured are 
shown. Cancer associations were determined as previously described (92). 
 
Full genome sequencing 
DNA was subjected to a nested limiting-dilution PCR protocol as previously described using Platinum Taq 
HiFi Polymerase (Life Technologies). The outer PCR was nearly full-length from HIV-1 reference genome 
HXB2 coordinates 623 to coordinates 9,686 and employed a touchdown-PCR protocol (72, 73). The outer-
PCR wells were diluted with deionized water and a small amount of outer-PCR DNA was used for nested 
amplification of both gag and env to determine clonality. Clonality was determined using Poisson 
statistics and at dilutions that gave a high probability of clonality (P > 0.85); all wells that were positive 
for outer PCR were subjected to six inner PCRs. 1 μl of outer-PCR DNA was used for each nested inner PCR 
reaction. PCR products were visualized on 1% agarose gels. The products were directly sequenced to 
minimize PCR-induced error, using the QIAquick Gel Extraction Kit followed by Sanger sequencing. 
Sequencing reads from the six overlapping nested PCRs were aligned and compared to the reference HIV -
1 genome HXB2 using CodonCode Aligner software to reconstruct near full length sequences and identify 
defects. Hypermutation was determined by using the full-length sequence for each clone and the Los 





Analysis of HIV proviral sequences  
Evaluation of cure strategies requires assays that not only detect infected cells, but also determine 
whether the proviruses they carry are intact so that reductions in the relevant population of proviruses are 
apparent despite the vast excess of defective proviruses. We assembled a database of 431 published (73, 88) 
full genome HIV-1 sequences obtained by single genome analysis from 28 HIV-1-infected adults (see 
Methods) and used it to determined how well PCR assays meet these requirements. Consistent with previous 
reports (73, 88, 89, 93, 94), only 2.4% of proviruses from treated individuals were intact (defined here as 
lacking overt fatal defects). The remaining 97.6% had fatal defects including deletions and/or G to A 
hypermutation (Fig. 6a). Because deletions were large (encompassing on average 49.6% of the genome) and 
because hypermutation altered start codons and/or introduced multiple stop codons in most ORFs (73, 92), 
most defective proviruses had defects affecting most HIV-1 genes (Fig. 6b). For example, most defective 
proviruses (80-97%) had defects in the transcriptional activator Tat (Fig. 6b) and are unlikely be efficiently 
transcribed after latency reversal. Thus, cure intervention dependent on viral gene expression (30, 31, 95, 96) 
may affect cells with intact and defective proviruses differently. Unfortunately, standard PCR assays use short 
subgenomic amplicons in conserved regions (Fig. 6c,d) and do not distinguish intact and defective proviruses. 
Deletions occur throughout the genome (Fig. 6e) affecting the fraction of proviruses detected (Fig. 6f) and the 
fraction of detected proviruses that are intact (Fig. 6g). Importantly, for most standard PCR assays, <10% of 
the detectable sequences are intact (Fig. 6g). For widely used assays targeting gag, only 6.6% of detected 
sequences are intact (Fig. 6g). Cells carrying these proviruses are hence less likely to be eliminated by “shock 
and kill” strategies. Importantly, the efficacy of a cure intervention causing a selective one log reduction in 
intact proviruses would not be readily detected by standard PCR assays but would be easier to detect with an 




































Fig. 6: Standard DNA and Alu-PCR assays predominantly measure defective proviruses.  
(A) Landscape of proviruses persisting in individuals on suppressive ART as detected by full length, single 
genome analysis of proviruses in CD4+ T cells. Defects include internal stop codons, deletions not attributable 
to normal HIV-1 length polymorphisms, and APOBEC3G/F-mediated hypermutation (G→A). Most deletions 
were large except for those in the packaging signal (ψ)/major splice donor site. Hypermutation occurred with 
or without deletions. Proviruses lacking deletions, hypermutation, and internal stop codons are termed intact 
but may harbor minor defects affecting viral fitness. Analysis based on 211 full genome sequences from 
individuals initiating ART during chronic infection. The proviral landscape in patients starting ART during 
acute infection is also dominated by defective sequences, with a slightly higher fraction showing 
hypemutation.  
(B) Fraction of defective sequences with inactivating defects in the indicated genes or elements. Protein-
coding genes were considered defective if any of the following are present: mutated start codon, internal stop 
codons, frameshifts, or insertions or deletions not representing common length polymorphisms. Splice donor 
and acceptor site mutations are also present in many sequences, and, if included, would further increased the 
fraction of defective sequences for genes requiring splicing (lighter shaded portions of the bars for spliced 
genes). LTR sequences were considered defective if mutations in the NFκB sites and/or deletions were 
present.  
(C) Positions of amplicons used in standard DNA and Alu-PCR assays (bottom) relative to HIV-1 genome map 
(top). Numbers distinguish distinct assays targeting the same region. Alu PCR assays 1 and 2 amplify host 
genomic sequence (arrows) in addition to the indicated regions of the provirus.  
(D) Conservation of nucleotide sequence across the genome based on US clade B sequences in the Los Alamos 
HIV Sequence Database (https://www.hiv.lanl.gov/). Plotted as % of sequences matching the consensus at 
each nucleotide.  
(E) Position of internal deletions across the HIV-1 genome. Plotted as % of total sequences from treated 
patients that are deleted at the indicated nucleotide. Terminal deletions preclude integration and are not 
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seen. Internal deletions in the 5’ LTR are not evaluable because the full genome sequencing methods do not 
capture this region. 
(F) Percent of all proviruses that are amplified by the indicated assay. Based on absence of overlap between 
deleted regions and the relevant amplicons.  
(G) Percent of the proviruses detected by the indicated assay that are intact by the above criteria.  
(H) Percent loss of assay signal following a selective 10-fold reduction in intact proviruses. For panels f-h, 
analysis is based on sequences from the most common group, individuals starting ART during chronic 





Development and validation of intact proviral DNA assay (IPDA) 
Interrogating individual proviruses simultaneously at multiple positions could differentiate intact 
from defective proviruses. Analysis of full genome sequences revealed that two strategically placed amplicons 
in the packaging signal (Ψ) and env regions could identify >90% of deleted proviruses as defective (Fig. 7a). 
Requiring that individual proviruses give amplification for both Ψ and env amplicons dramatically reduces 
PCR overestimate of reservoir size. The remaining overestimate is due largely to hypermutated proviruses 
(Fig. 6a). Among proviruses with statistically confirmed (89) G to A hypermutation, 73% had mutations in the 
GG to AG context. Most also had GA to AA mutations. 27% had only GA to AA hypermutation, but most of these 
also had deletions that would identify then as defective. Therefore, we developed a way to distinguish intact 
proviruses from those with the common GG to AG hypermutation pattern. We identified a conserved region 
within the Rev response element (RRE) that contains adjacent consensus sites (TGGG) for responsible 
enzyme, APOBEC3G (97, 98) (Fig. 7b-e). Of sequences with GG to AG hypermutation, 97% had one or more 
mutations in this region (Fig. 7c,e), with 13 distinct patterns (Fig. 7f). Allelic discrimination probes targeting 
this region were developed and tested using a set of mutant plasmids each carrying one of the 13 sequence 
patterns in quantitative PCR (qPCR) and digital droplet PCR (ddPCR) studies to validate a probe combination 
that correctly identified 95% of the hypermutated sequences as defective (Fig. 7f). The above analyses 
allowed design of a simple, rapid multiplex ddPCR assay that distinguishes deleted and/or hypermutated 
proviruses from intact proviruses using two PCR amplicons and hypermutation discrimination probes (Fig. 
8a,b). Genomic DNA (gDNA) is isolated using an optimized method to minimize DNA shearing between 
targeting regions (see below) and partitioned into nanodroplets such that individual droplets rarely contain 
>1 provirus (P = 0.00416). Proviruses within droplets are analyzed simultaneously at the Ψ and env regions 
via multiplex PCR, with the env PCR also discriminating hypermutated proviruses. Intact proviruses give 
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CCTTAGGTTCTTAGGA  36  -
CCTTAAGTTCTTAAGA  23  -
CCTTAGGTTCTTAAGA  13  -
CCTTAAGTTCTTAGGA  11  -
CCTTGGGTTCTTGGGA   3  +
CCTTAGGTTCTTAGAA   2  -
CCTTAGGTTCTTGAAA   2  -
CCTTAGGTTCTTGAGA   2  -
CCTTAAGTTCTTAAAA   1  -
CCTTAAGTTCTTAGAA   1  -
CCTTGAGTTCTTAGGA   1  -
CCTTAGGTTCTTGGGA   1  +
CCTTGGGTTCTTAGGA   1  +
Fraction of deleted sequences
correctly identified as defective
















































































































































amplification at both regions (Fig. 8a,b). The number of intact proviruses per 106 cells is calculated using 












Fig. 7: Use of full genome sequences to position amplicons for distinguishing intact and defective HIV-1 
proviruses.  
(A) Sliding window analysis of optimal amplicon positioning. Analysis assumes two amplicons 100 bp in 
length are used to detect deletions. Starting positions of the 5′ and 3′ amplicons are shown on the horizontal 
and vertical axes, respectively, relative to the HIV-1 genome map. See Fig. 6 for color code of HIV-1 genes. 
Heat map color scale indicates fraction of deleted proviruses correctly identified as defective by overlap of 
one or both amplicons with the deletion. Optimal discrimination between intact and deleted sequences is 
obtained with a 5′ amplicon in the Ψ region and a 3′ amplicon in env. Ψ is the site of frequent small deletions 
and is included in larger 5′ deletions. Based on 258 distinct full genome sequences in the database that 
contains mapped deletions.  
(B) Degree of nucleotide conservation across the HIV-1 env gene based on US clade B sequences in the Los 
Alamos HIV Sequence Database. Conservation is plotted as percent of sequences matching the consensus 
sequence at each nucleotide position. The shaded area is expanded in Fig. 7d.  
(C) GG→AG pattern hypermutation across the HIV-1 env gene. The percent of hypermutated proviruses that 
contain one or more G→A mutations within a given APOBEC3G consensus site is plotted as a function of site 
position. The shaded area is expanded in Fig. 7e.  
(D) Sequence conservation of a region in the RRE containing two APOBEC3G consensus sites. The positions of 
primers (arrows) and probe (box) for the env amplicon selected for the intact proviral DNA assay are shown. 
(E) Fraction of hypermutated proviruses that have one or more G→A mutations in the adjacent consensus 
sites in region chosen for probe binding (shaded).  
(F) Summary of the hypermutation patterns found at the env probe-binding site. The prevalence of each of 
the 13 distinct patterns observed is indicated in the bar graph on the left and in the “Percent” column. 
Mutations in the APOBEC3G consensus sites (underlined) are indicated in red. Based on analysis of 93 
independent hypermutated env sequences from 18 patients treated during either chronic or acute infection. 
Site directed mutagenesis was used to modify NL4-3 or a patient-derived proviral construct to generate 
plasmids containing each of these hypermutation patterns. The “Amplified” column indicates that only 5% of 
hypermutated sequences were amplified by the probe combinations developed to identify intact sequences. 
See Table S3 for details. 
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The specificity of this intact proviral DNA assay (IPDA) was verified using plasmid controls 
representing proviruses with different types of defects. These templates gave positive droplets in the 
expected quadrants: Q1, 3′ deletion and/or hypermutation; Q4, 5′ deletion. More importantly, cultured clonal 
populations of infected patient cells also give single quadrant patterns (see below). In contrast, uncultured 
polyclonal patient CD4+ T-cell populations give positive droplets in all three quadrants, allowing separate 
quantitation of intact and defective proviruses (Fig. 8c). 
Extensive validation of IPDA reproducibility and linearity is provided in Figs. 9 and 10. An important 
issue is DNA shearing which is essential for droplet formation but artificially reduces the number of Q3 
droplets while increasing Q1 and Q4 droplets. To control for shearing, a separate multiplex ddPCR 
amplification of two regions of a cellular gene (RPP30) spaced at exactly the same distance as the Ψ and env 
amplicons is done on every sample. This gives a DNA shearing index (DSI) that is used to correct raw HIV-1 
ddPCR results. To validate this approach, DNA from JLat cells (99), which contain a single integrated HIV-1 
genome, was subjected to different amounts of shearing and analyzed by ddPCR for HIV- 1 and RPP30. 
Regardless of the degree of shearing, the DSI was similar for HIV-1 and RPP30 indicating that RPP30 shearing 
can be used to correct for HIV-1 shearing (Fig. 8d). At all levels of shearing tested, results corrected for 
shearing were close to the expected values of 1 copy/cell for HIV-1 (Fig. 8e) and 4 copies/cell for RPP30 (JLat 
cells are tetraploid for this gene). Thus, the assay can reliably quantitate intact proviruses in most DNA 
samples after correction for shearing. 
Using samples of only 5x106 cells, we measured intact and defective proviruses with the IPDA in a 
large number (n=62) of infected individuals who had suppression of viremia on antiretroviral therapy (ART) 
(n=57) or control of HIV-1 without ART (“elite” control, n=5) (see Table 2 for characteristics of study 
participants). The mean DSI for this sample set was 0.323±0.067, well within the range for which accurate 
correction is possible. Intact HIV-1 proviruses were rare (~100/106 resting CD4+ T cells) and greatly 
outnumbered by proviruses with 5′ deletions and by proviruses with 3′ deletions and/or hypermutation (Fig. 
8f). These results provide the first direct demonstrate with a method that does not depend on long PCR 





Fig. 8: Intact proviral DNA assay (IPDA).  
(A) Assay schematic. Multiplex PCRs in droplets amplify Ψ and env regions. Hydrolysis probes for each 
amplicon are labeled with different fluorophores. A separate multiplex PCR targets two regions of the human 
RPP30 gene spaced at the same distance as the Ψ and env amplicons to provide cell number quantitation and 
DNA shearing correction. See Methods for details.  
(B) Representative control ddPCR experiment using proviral constructs34 with a 5’ deletion (E44E11), a 3’ 
deletion (4F11), or no defects (NL4-3). 1,000 copies each were mixed with 500ng of HIV-1 negative DNA to 
simulate a patient sample. Types of proviruses appearing in different quadrants are shown on the right.  
(C) Representative IPDA results from a patient CD4+ T-cell sample. Boxed areas are expanded to show 
individual positive droplets.  
(D) DNA shearing index (DSI, fraction of templates sheared between targeted regions) measured for RPP30 
and HIV-1 on JLat DNA subjected to different levels of shearing.  
(E) Use of DSI to correct raw ddPCR output for RPP30 and HIV. Copies/cell of RPP30 (blue) and HIV (orange) 
























































































































































counts in Q2 and increases counts in Q1 and Q4. Correction brought Q2 values for close expected values (1 
copy/cell for HIV and 4 copies/cell for RPP30 (tetraploid for RPP30).  
(F) IDPA results on CD4+ T-cells from infected individuals with plasma HIV-1 RNA below the limit of 
detection. See Table 2 for patient characteristics.  
(G) Correlation between infected cell frequencies measured by QVOA and IPDA on the same samples of CD4+ 
T-cells from treated patients. IUPM, infectious units per million cells.  
(H) IPDA/QVOA ratios for samples from Fig. 8g.  
(I) Bioinformatic comparison of standard gag PCR and IPDA with respect to % of proviruses amplified, % of 
amplified proviruses that are intact, and % loss in assay signal following a selective 10 fold reduction in intact 
























Fig. 9: IPDA reproducibility. Frequencies of cells containing proviruses with 3′ deletions and/or 
hypermutation (A), 5′deletions (B), or no defects (intact) (C) in CD4+ T cells from 28 treated patients. Each 
data point represents a replicate IPDA determination from a single sample from the indicated patient. The 
mean and SEM of the replicates are plotted. The variability between patients is much greater than the 




Fig. 10: Linearity of the IPDA.  
(A) Standard curve generated using dilutions of the intact proviral reference plasmid NL4-3, with (light blue) 
or without (dark blue) added genomic DNA (gDNA) from HIV-1-negative PBMCs.  
(B) Standard curve generated a characterized an HIV-1 infected cell line with (purple) or without (green) 
added gDNA. The HIV-1 cell line was generated by infecting Jurkat cells with a single-round GFP virus and 
sorting for GFP+ cells. The culture was further characterized to verify it contained the correct HIV-1 sequence 
































































y = 0.626x; R2 = 0.9979
NL4-3 plasmid + gDNA
y = 0.4579x; R2 = 0.9797 
HIV-1-infected culture 
y = 0.724x; R2 = 0.9632
HIV-1-infected culture + gDNA
y = 0.552x; R2 = 0.9910
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HIV latent reservoir change measured by QVOA and IPDA 
We next sought to determine if the frequency of intact proviruses measured by IPDA correlated with 
other reservoir measurements. We found strong correlations between IPDA and QVOA measurements on the 
same samples (r=0.48, p=0.003, n=35, Fig. 8g). Importantly, we did not expect a precise correlation between 
IPDA and QVOA. Previous studies have demonstrated that the fraction of intact, replication-competent 
proviruses induced by a single round of T-cell activation in the standard QVOA is small and more rounds of 
stimulation could induce additional intact proviruses (Fig. 8h). Using full genome sequences, we compared 
IPDA with the widely used gag PCR with respect to desired assay characteristics. IPDA detects a larger 
fraction of the total proviral population (Fig. 8i) and separately enumerates intact proviruses and two classes 
of defective proviruses. Most importantly, the majority of proviruses classified as intact by IPDA lack any 
defects detectable by full genome sequencing. In contrast, this value is <10% for standard gag PCR (Fig. 8i). As 
a result, the IPDA can detect intervention-induced reductions in intact proviruses that would not be apparent 
in standard assays (Fig. 8i). 
The latent reservoir measured by the QVOA undergoes slow decay (t1/2=44 months) (26, 100). To 
determine whether intact proviruses measured by IPDA show similar decay, we examined longitudinal 
samples from treated patients taken 2-8 years apart (Fig. 11a). For most patients, intact proviruses declined 
with a t1/2 of ~44 months (Fig. 11a,b). Some patients showed even slower decay (t1/2=100-300 months), 
and for 3/14 patients, there was no decay (Fig. 11b,c). Thus the IPDA can measure changes consistent with 
known reservoir dynamics and possibly define subpopulations with different dynamics. Remarkably, the 
dynamics of defective proviruses in the same patients showed much greater variability, with increases over 
time in some patients (Fig. 11a,c), which likely reflects proliferation of cells harboring defective proviruses. 
While the mean decay slopes were similar, the standard deviations of decay slopes were much greater for 
defective proviruses, complicating interpretation of assays that are dominated by these defective forms.  
 
Differential dynamics of cells carrying intact and defective proviruses  
Increases in infected cell frequency can reflect the proliferation of infected cells (63-68, 70, 101). We 
asked whether the differential dynamics of cells with intact and defective proviruses could be due to uneven 
distribution in subsets of memory CD4+ T-cells with different proliferative potential. Intact and defective 
 49 
proviruses were found in expected ratios in central, transitional, and effector memory subsets (Fig. 11d). We 
then asked whether intact and defective proviruses imposed different constraints on proliferation of infected 
cells. We used IPDA to track the fate of individual infected cells from treated patients following in vitro 
weekly stimulation with anti-CD3/28 (Fig. 11e). Microcultures seeded with ~1 infected cell/well were 
subjected to 4 rounds of stimulation in the presence of antiretroviral drugs prior to DNA isolation for IPDA, 
integration site analysis, and full genome sequencing. Analysis of >1700 microcultures showed that positive 
droplets were detected in only one of three possible quadrants for most positive wells, as expected for 
cultures initiated with a single infected cell (Fig. 11e). Most (97.6%) proviruses were defective (Fig. 11f). 
Importantly, the IPDA also counts proviruses in each well allowing direct quantitation of infected cell 
proliferation. Some cells carrying defective proviruses were capable of enormous clonal expansion (up to 
1000 fold) while cells with intact proviruses were rarely detected and showed little proliferative potential 
(Fig. 11f). These results demonstrate a profound proliferative defect in response to TCR stimulation for cells 
carrying intact proviruses relative to cells with defective proviruses. 
To determine whether proliferative potential was related to the site of integration (64, 65, 101), 
we analyzed integration sites of expanded clones as previously described (102). This analysis confirmed 
the clonality of these cultures and that integration in genes with cancer association was not required for 
proliferation (Fig. 11f, Table 3). Rather we hypothesized that proliferative potential was related to 
proviral defects. Full genome sequencing confirmed the clonal nature of the proviruses in each well and 
demonstrated directly that the IPDA correctly identifies the presence and nature of defects in proviruses 
(Fig. 11g). Of 12 clonally expanded proviruses sequenced, 9 were defective in all HIV-1 ORFs, and none 
were fully competent for expression of Tat or of Vif, Vpr, Vpu, Env, or Nef. Low or absent expression of 

























Fig. 11: IPDA reveals differential dynamics of intact and defective proviruses.  
(A) Decay of intact proviruses, proviruses with 3′ deletion and/or hypermutation (3′ del/hyper), and 
proviruses with 5′ deletions (5′ del) measured in resting CD4+ T cells from patients on long term suppressive 
ART. Time scale indicates years between sampling.  
(B) Half-lives of cells carrying intact proviruses calculated assuming exponential decay from the data in (a). 
Arrow indicates that t½ of the latent reservoir determined through QVOA.  
(C) Half-lives of populations of cells carrying intact and defective proviruses. For some patients, cells with 
defective proviruses increased over the time interval shown in (a), and thus a doubling time is displayed. 
(D) Distribution of intact and defective proviruses in memory CD4+ T-cell subsets.  
(E) Experimental system for examining the proliferation of infected cell clones. Resting CD4+ T-cells were 
isolated from patients on ART. The total number of proviruses was measured using a standard gag PCR that 
detects both intact and defective proviruses (Fig. 6). After correction for gag deleted proviruses, cells were 
diluted to approximately 1 infected cell per well (2000-4000 total resting CD4+ T-cells/well) and subjected 2-
4 rounds of stimulation with anti-CD3+anti-CD28 microbeads in the presence of IL-2 and antiretroviral 
drugs as described in Methods. Over the course of this culture, the cells in each well expanded to an average 
of 2x106 cells/well. DNA was isolated for IPDA and for integration site analysis and full genome sequencing, 
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performed as previously described. IPDA analysis generally showed positive droplets in only one of 
the three possible quadrants, confirming the clonal nature of the cultures and the efficacy of the 
antiretroviral drugs.  
(F) IPDA and integration site analysis of 1731 microcultures from 5 patients. Y-axis indicated 
number of proviruses in each positive culture. Colors indicate type of provirus detected. Bars 
indicate geometric mean number of proviruses per culture for each type of proviruses. The 
statistical significance of differences between numbers of proviruses per positive culture for each 
type is given at the top of each panel (* = p<0.05, ** = p<0.01, *** = p<0.005). Integrations site 
analysis was performed on positive cultures as described in Methods. Sites for some of the clones 
with the highest levels of proliferation are indicated in blue boxes. Pie charts indicate the fractions 
of integration sites in transcriptional units, intergenic regions, or with cancer associations for 
cultures with high (> 20 proviruses, top) or low (< 20 proviruses, bottom) proliferation.  
(G) Full genome sequencing results for cultures showing proliferation. Sequences were analyzed for 
defects affecting expression of each HIV-1 gene as described in the legend to Fig. 6b. Count indicates 







The failure of cells carrying intact proviruses to expand in response to TCR stimulation provides 
insights into the mechanisms driving in vivo expansion of cells capable of producing infectious virus and into 
cure strategies involving T-cell activation. So far, several mechanisms have been proposed to induce 
proliferation of HIV-infected CD4+ T cells, including antigen stimulation, homeostatic proliferation and 
proliferation dependent on HIV integration site (64, 65, 70, 101). Our results suggest that antigen stimulation 
through CD3/CD28 costimulation is likely to induce viral expression in CD4+ T cells carrying replication-
competent provirus, leading to cell death. This hypothesis is consistent with our observation that cellular 
clones carrying replication-competent HIV wax and wane on a time scale of years rather than persisting 
overtime. Therefore the role of antigen stimulation in HIV persistence requires further investigation. 
Additionally, we have shown previously that proliferation of HIV-infected cells is common in infected 
individuals and the extent of proliferation is significant. Therefore the slow decay of the latent reservoir 
measured by QVOAs must reflect ongoing proliferation balanced by cell death (103). Certain level of T-cell 
activation may speed up the decay of cells carrying intact proviruses since they showed limited proliferation 
potential upon TCR stimulation. Mathematical modeling suggests that a 20% reduction in proliferation rate 
could dramatically decrease the half-life of the latent reservoir. Therefore we should reconsider the 
possibility of shock and kill strategy and include latency-reversing agents that induce some level of viral 
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expression in infected cells without causing global T cell activation. Our results show that the small subset of 
proviruses with the potential to cause viral rebound show different dynamics than the vast excess of defective 
proviruses captured in standard PCR assays, emphasizing the importance of direct measurement of intact 
proviruses. Limit of detection and dynamic range are two of the biggest constraints of current assays, 
especially in the context of interventions studies and large-scale clinical trials involving new cure strategies. 
As discussed above, PCR-based assays that are used in most current studies are efficient but they could not 
distinguish intact from defective proviruses that are clinically irrelevant. Assays that allow direct 
quantification of replication-competent proviruses are time-consuming and give us an underestimate of the 
reservoir size. The availability of a scalable assay for direct measurement of intact proviruses should 




















Table S1. Clinical characteristics of study subjects 
Study ID    Age Sex    Year of HIV diagnosis   CD4 nadir    Years on ART ART regimen
S09 38 F 1992 275 6 ABC/DTG/3TC
S10 53 M 1997 184 10 FTC/RPV/TDF
S11 63 M 2001 41 16 FTC/RPV/TAF
S03 52 F 1999 320 18 ABC/DTG/3TC
S02 59 F 2004 159 10 FTC/TAF
S01 55 F 1995 204 10 RPV/FTC/TAF/DTG
S12 44 M 1994 105 9 EVG/COBI/FTC/TAF
S08 51 M 1990 39 15 DRV/COBI/DTG
S05 67 M 1992 unknown 25 ABC/ETR/3TC/RAL
S06 54 F 1998 89 10 DRV/r, FTC, RAL
S04 55 M 1994 162 10 EFV/FTC/TAF
S07 57 F 1990 328 8 DRV, RAL/r, MVC
S13 61 M 1996 214 21 DTG, 3TC, DRV/r
S14 55 M 1991 8 10 EVG/COBI/FTC/TAF
S15 69 M 1994 144 14 DRV, DTG/r
Drug abbreviations ABC, abacavir; COBI, cobicistat; DR V, darunavir; DTG, dolutegravir; EFV, efavirenz; EVG, elvitegravir; ETR, 
etravirine; FTC, emtricitabine; MVC, maraviroc; RAL, raltegravir; RP V, rilpivirine; TAF, tenofovir alafenamide; TDF, tenofovir 
disoproxil fumarate; 3TC, lamivudine; /r , boosted with ritonavir .
S16 54 M 1998 113 9 FTC/RPV/TDF
































































AP01 44 M AA ABC/3TC/DTG 687 <20 121 115 CP 
AP02 36 F AA EVG/TAF/FTC/COBI 840 <20 78 77 CP 
AP04 52 M W EVG/TDF/FTC/COBI NA <20 79.0 70 CP 
AP05 44 F AS ABC/3TC/DTG NA <20 41.3 40 CP 
AP07 47 M W FTC/TDF, DTG NA <20 15.2 8 CP 
AP08 40 M W FTC/TDF, RAL NA <20 32.1 28 CP 
AP09 33 M W ABC/3TC/DTG NA <20 24.3 20 CP 
AP10 31 M AS ABC/3TC/DTG NA <20 14.8 13 CP 
CP01 63 M AA ETR, FTC, RAL 907 <20 101 100 CP 
CP02 61 M AA ABC/3TC, DRV/r, RAL 423 <20 46 44 CP 
CP03 76 M W ABC/3TC/ZDV, ATZ/r 635 <20 192 177 CP 
CP04 49 F AA DRV/r, EFV/FTC/TDF 890 <20 210 55 CP 
CP04 51 F AA EVG/TAF/FTC/COBI 582 <20 229 74 CP 
CP05 55 F AA ABC, FTC, ETR, RAL 441 <20 199 104 CP 
CP06 63 M W ABC, 3TC, RAL, ETR 997 <20 253 50 CP 
CP07 36 M AA EFV/FTC/TDF NA <20 61 55 CP 
CP07 40 M AA ABC/3TC/DTG 976 <20 108 102 CP 
CP08 47 M AA ETR, MVC, RAL 829 <20 163 78 CP 
CP09 50 M AA 3TC, DRV/r, RAL 1635 <20 143 101 CP 
CP10 58 M AA ETR, DRV/r, RAL 570 <20 >208 120 CP 
CP11 53 M W ABC/3TC/DTG 912, 1214 <20 43 30 CP 
CP12 54 M AA 3TC/ZDV, EFV, ATV/r 586 <20 264 135 CP 
CP13 70 M W EFV/FTC/TDF 665 <20 224 161 CP 
CP14 56 M AA EFV, DRv/r, RAL 1011 <20 187 179 CP 
CP15 55 M AA EFV, FTC/TAF 1550 <20 130 112 CP 
CP16 53 M AA FTC/TAF, RAL 788 <20 108 62 CP 
CP17 57 F AA ABC/3TC/DTG 802 <20 107 92 CP 
CP18 49 F AA EVG/TAF/FTC/COBI 1086 <20 52 45 CP 
CP19 53 F AA None 535 2130 N/Ag N/Ag CP 
CP20 49 F AA ABC/3TC/DTG 623 <20 107 98 CP 
CP21 38 F AA ABC/3TC/DTG 1098 <20 64 60 CP 
CP22 57 F AA DRV/r, MVC, RAL 976 <20 92 90 CP 





























CP24 58 F AA ETR, DRV/r, RAL 752,  1146 <20 92 38 CP 
CP25 67 F AA FTC/RPV/ TAF 482 <20 153 142 CP 
CP26 44 M AA EFV/FTC/TDF 495 454 <20 97 94 CP 
CP27 63 M AA EFV/FTC/TDF 502 <20 87 73 CP 
CP28 50 M AA DRV/COBI,  DTG 553 <20 121 111 CP 
CP29 60 M AA EFV, ABC/3TC 452 <20 189 151 CP 
CP30 64 M W ETR, 3TC, TDF NAh <20 NA 127 CP 
CP31 64 M W NNRTI regimen 1750, 1748 <50, <20 NA 72, 170 CP 
CP33 67 M W NNRTI regimen 659, 721 <50, <20 NA 45, 114 CP 
CP35 69 M AA PI regimen 371, 635 <50, <20 NA 8, 74 CP 
CP37 74 M W PI regimen 618, 771 <50, <50 NA 19, 85 CP 
CP39 71 M W NNRTI+PI regimen 529, 435 <50, <20 NA 91, 151 CP 
CP41 74 M W NNRTI regimen NA, 739 <50, <50 NA 65, 130 CP 
CP43 61 M AA PI regimen 760, 484 <50, <20 NA 74, 140 CP 
CP45 49 M AA PI regimen 296, 655 <50, <20 NA 105, 171 CP 
CP47 40 M W NNRTI regimen 715, 768 <20, <20 NA 47, 108 CP 
CP49 49 M W NNRTI regimen 599, 931 <20, <20 NA 58, 117 CP 
ES24 64 M AA None 1500 < 20 N/A N/A EC 
ES3 65 F AA None 1149 <20 N/A N/A EC 
ES31 64 F AA None 744 <20 N/A N/A EC 
ES46 50 M AA None 612 <20 N/A N/A EC 
ES5 65 F AA None 735 <20 N/A N/A EC 
 
aAA, African American; AS, Asian; W, white. 
bStandard drug abbreviations are used.  “/” indicates drugs combined into a single pill.  For 
some cryopreserved samples from MACS cohort participants, regimen details are not available 
an information on whether the regimen contained a non-nucleoside reverse transcriptast 
inhibitor (NNRTI) or a protease inhibitor (PI). 
cAt time of sampling. 
dTotal time on ART. 




   













CP04 chr5-80876827 chr5+80876823 MSH3 3' del/h 32 +  + 
CP04 chr5-80876827 chr5+80876823 MSH3 5' del 12 +  + 
CP04 chr19+34451344 chr19-34451348 UBA2 5' del 28 + +  
CP04 chr19+34451344 chr19-34451348 UBA2 3' del/h 32 + +  
CP04 chr1-35495247 chr1+35495243 KIAA0319L 3' del/h 64  +  
CP04 chr7-106102652 chr7+106102648 SYPL1 5' del 24  +  
CP04 chr19+35190297 chr19-35190301 FXYD5 3' del/h 20   + 
CP07 chr17-32199245 chr17-32199249 RHOT1 5' del 16  +  
CP07 chr3-98519105 chr3-98519101 CLDND1 3' del/h 308  +  
CP07 chr1+113782457 chr1-113782461 RSBN1 3' del/h 292  +  
CP07 chr17-44145548 chr17-44145552 C17orf53 3' del/h 96  +  
CP07 chr6+136733815 chr6+136733811 MAP3K5 3' del/h 8  +  
CP07 chr16+27412884 chr16-27412888 LOC105369891 3' del/h 8    
CP08 chr16+67046878 chr16-67046882 CBFB 3' del/h 16  + + 
CP08 chr17+42262488 chr17-42262492 STAT5B 3' del/h 20  + + 
CP08 chr17+42240249 chr17-42240253 STAT5B 3' del/h 24  + + 
CP08 chr2+9594060 chr2-9594064 YWHAQ 3' del/h 56  +  
CP08 chr17+60468915 chr17-60468919 APPBP2 5' del 12  +  
CP08 chr19-47092528 chr19+47092524 ZC3H4 3' del/h 4  +  
CP08 chr8+60557609 chr8-60557613 RAB2A 3' del/h 4  +  
CP08 chr2+61079679 chr2-61079683 KIAA1841 3' del/h 8  +  
CP08 chr7-75478021 chr7+75478017 POM121C 3' del/h 4  +  
CP08 chr17+47475167 chr17-47475171 MRPL45P2 3' del/h 4  +  
CP08 chr15-78491538 chr15+78491534 IREB2 3' del/h 4  +  
CP08 chrX+79360929 chrX-79360933 ITM2A 3' del/h 164  +  
CP08 chr1-160517973 chr1+160517969 SLAMF6 3' del/h 8  + + 
CP08 chr6-13719937 chr6+13719933 RANBP9 3' del/h 28    
CP08 chr17+42263312 chr17-42263316 STAT5B 3' del/h 4  + + 
CP08 chr6+90030225 chr6-90030229 BACH2 3' del/h 8  + + 
CP08 chr16-24750574 chr16+24750570 TNRC6A 3' del/h 8  +  
CP08 chr7+128564161 chr7-128564165 METTL2B 5' del 12    
CP08 chr2+190667403 chr2-190667407 NAB1 3' del/h 28  +  
CP08 chr7+72887790 chr7-72887794 POM121 3' del/h 4  +  
CP08 chr19+57845452 chr19-57845456 ZNF587B 3' del/h 68  +  
CP08 chr17+55289949 chr17-55289953 HLF 5' del 4  + + 
CP08 chr11+123370535 chr11-123370539 MIR4493 3' del/h 4    
 
 









































CP08 chr7-5692004 chr7+5692000 RNF216 3' del/h 8  + + 
CP08 chr16+30296748 chr16-30296752 SMG1P5 3' del/h 16  +  
CP08 chr11-75347724 chr11+75347720 ARRB1 3' del/h 28  +  
CP08 chr5+176497230 chr5-176497234 FAF2 3' del/h 160  +  
CP08 chr6-42778282 chr6+42778278 GLTSCR1L 5' del 12  +  
CP08 chr6-26915454 chr6+26915450 GUSBP2 3' del/h 4  +  
CP08 chr6-135036395 chr6+135036391 HBS1L 3' del/h 4  +  
CP08 chr12-65250700 chr12+65250696 LEMD3 3' del/h 8    
CP08 chr3-196305363 chr3+196305359 TCTEX1D2 3' del/h 4  +  
CP08 chr19+12328836 chr19-12328840 ZNF563 5' del 4  +  
CP08 chr7-110998623 chr7+110998619 IMMP2L 3' del/h 4  +  
CP08 chr13+74007800 chr13-74007804 KLF12 3' del/h 4  +  
CP08 chr11-73752097 chr11+73752093 RAB6A 3' del/h 8  +  
CP08 chr9+3295869 chr9-3295873 RFX3 3' del/h 24  +  
CP08 chr9+132308637 chr9-132308641 SETX 3' del/h 16  +  
CP08 chr11-121540206 chr11+121540202 SORL1 3' del/h 4  + + 
CP08 chr17-61074679 chr17+61074675 BCAS3 3' del/h 1280  + + 
CP08 chr19-15290881 chr19+15290877 BRD4 5' del 24  + + 
CP08 chr11-108718192 chr11+108718188 DDX10 3' del/h 4  + + 
CP08 chr9-3522329 chr9+3522325 RFX3 5' del 16  +  
CP08 chr12-56044087 chr12+56044083 RPS26 5' del 8  +  
CP08 chr16+29557050 chr16-29557054 SMG1P2 3' del/h 16  +  
CP08 chr6+149336745 chr6-149336749 TAB2 3' del/h 4  +  
CP08 chr16-2493872 chr16+2493868 TBC1D24 3' del/h 4  +  
CP08 chr17+62510253 chr17-62510257 TLK2 5' del 12  +  





















aIntegration sites were determined using a previously described10-12 linker ligation method with HIV-1 
primers in the U3 region of the 5’ LTR and the U5 region of the 3’ LTR. Only sites detected with both U3 and 
U5 primers are reported. This column gives the U3 site.  
bLocation of integration site detected with U5 primer. 
cName of gene containing the integration site. In cases where the integration site is intergenic, the name of the 
nearest transcriptional unit is given13. 
dNature of provirus detected by IPDA in cells from individual microculture wells. 3’ del/h indicated provirus 
with a 3’ deletion and/or hypermutation. 5’ del indicated provirus with a 5’ deletion. Cells with intact 
proviruses did not expand sufficiently for integration site analysis. 
eNumber of proviruses present in microculture as determined by IPDA droplet count adjusted for fraction of 
DNA used in IPDA. 
fIdentical integration site detected in >1 independent microculture from a single donor. 
gIntegration site located within a transcriptional unit. 
hIntegration site within or near a gene which has been associated with some form of cancer in previous 
studies as defined in reference 13. 
 
 













Ψ F 692-711  CAGGACTCGGCTTGCTGAAG 
Ψ R 797-775a  GCACCCATCTCTCTCCTTCTAGC 
Ψ Probe 758-740a FAM, MGBb TTTTGGCGTACTCACCAGT 
Env F 7736-7759  AGTGGTGCAGAGAGAAAAAAGAGC 
Env R 7851-7832a  GTCTGGCCTGTACCGTCAGC 
Env intact probe 7781-7796 VIC, MGB CCTTGGGTTCTTGGGA 



















bMGB, minor groove binder. 
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